<!DOCTYPE html>
<html lang="en" xmlns:og="http://ogp.me/ns#" xmlns:fb="https://www.facebook.com/2008/fbml">
    <head>
        <meta charset="utf-8">
        <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
        <title>Molecules  | Free Full-Text | Design, Synthesis and Anticancer Evaluation of Novel Quinazoline-Sulfonamide Hybrids | HTML</title><link rel="stylesheet" href="http://img.mdpi.org/assets/css/jquery-ui-1.10.4.custom.min.css?63fcc31cab108f00">
        <link rel="stylesheet" href="http://img.mdpi.org/assets/css/font-awesome.min.css?feda974a77ea5783">
        <link rel="stylesheet" href="http://img.mdpi.org/assets/css/main.css?7de3785de19c3740">
        <link rel="shortcut icon" href="http://img.mdpi.org/favicon.ico?2cc1a03f42824a2d">
                            <link rel="stylesheet" media="all" type="text/css" href="/journal/molecules/css">
        <link rel="stylesheet" href="http://img.mdpi.org/assets/css/article-html.css?ba9b57c88b775ff7">
    <meta name="title" content="Design, Synthesis and Anticancer Evaluation of Novel Quinazoline-Sulfonamide Hybrids">
	<meta name="description" content="By combining the structural features of quinazoline and sulfonamides, novel hybrid compounds 2–21 were synthesized using a simple and convenient method. Evaluation of these compounds against different cell lines identified compounds 7 and 17 as most active anticancer agents as they showed effectiveness on the four tested cell lines. The anticancer screening results of the tested compounds provides an encouraging framework that could lead to the development of potent new anticancer agents." >
	<link rel="image_src" href="http://img.mdpi.org/img/journals/molecules-logo.png?97552ead561a93b2" >
	<meta name="dc.title" content="Design, Synthesis and Anticancer Evaluation of Novel Quinazoline-Sulfonamide Hybrids">

            <meta name="dc.creator" content="Mostafa Ghorab">
            <meta name="dc.creator" content="Mansour Alsaid">
            <meta name="dc.creator" content="Mohammed Al-Dosari">
            <meta name="dc.creator" content="Marwa El-Gazzar">
            <meta name="dc.creator" content="Mohammad Parvez">
    
    <meta name="dc.type" content="Article">
    <meta name="dc.source" content="Molecules 2016, Vol. 21, Page 189">
    <meta name="dc.date" content="2016-02-04">
            <meta name ="dc.identifier" content="10.3390/molecules21020189">
    
    <meta name="dc.publisher" content="Multidisciplinary Digital Publishing Institute">
    <meta name="dc.rights" content="http://creativecommons.org/licenses/by/3.0/">
    <meta name="dc.format" content="application/pdf" >
    <meta name="dc.language" content="en" >
	<meta name="dc.description" content="By combining the structural features of quinazoline and sulfonamides, novel hybrid compounds 2–21 were synthesized using a simple and convenient method. Evaluation of these compounds against different cell lines identified compounds 7 and 17 as most active anticancer agents as they showed effectiveness on the four tested cell lines. The anticancer screening results of the tested compounds provides an encouraging framework that could lead to the development of potent new anticancer agents." >

            <meta name="dc.subject" content="synthesis" >
            <meta name="dc.subject" content="quinazoline" >
            <meta name="dc.subject" content="sulfonamides" >
            <meta name="dc.subject" content="anticancer activity" >
    
    <meta name ="prism.publicationName" content="Molecules">
    <meta name ="prism.publicationDate" content="2016-02-04">
    <meta name ="prism.volume" content="21">
    <meta name ="prism.number" content="2">
    <meta name ="prism.section" content="Article" >
    <meta name ="prism.startingPage" content="189" >

    
    <meta name="citation_journal_title" content="Molecules">
    <meta name="citation_publisher" content="Multidisciplinary Digital Publishing Institute">
    <meta name="citation_authors" content="Ghorab, Mostafa M.; Alsaid, Mansour S.; Al-Dosari, Mohammed S.; El-Gazzar, Marwa G.; Parvez, Mohammad K.">
    <meta name="citation_title" content="Design, Synthesis and Anticancer Evaluation of Novel Quinazoline-Sulfonamide Hybrids">
    <meta name="citation_date" content="2016-02-04">
    <meta name="citation_volume" content="21">
    <meta name="citation_issue" content="2">
    <meta name="citation_firstpage" content="189">

    
            <meta name="citation_doi" content="10.3390/molecules21020189">
    
    <meta name="citation_id" content="mdpi-molecules21020189">
    <meta name="citation_abstract_html_url" content="http://www.mdpi.com/1420-3049/21/2/189">
            <meta name="citation_pdf_url" content="http://www.mdpi.com/1420-3049/21/2/189/pdf">
        <link rel="alternate" type="application/pdf" title="PDF Full-Text" href="http://www.mdpi.com/1420-3049/21/2/189/pdf">
        <meta name="fulltext_pdf" content="http://www.mdpi.com/1420-3049/21/2/189/pdf">
                <meta name="citation_fulltext_html_url" content="http://www.mdpi.com/1420-3049/21/2/189/htm">
        <link rel="alternate" type="text/html" title="HTML Full-Text" href="http://www.mdpi.com/1420-3049/21/2/189/htm">
        <meta name="fulltext_html" content="http://www.mdpi.com/1420-3049/21/2/189/htm">
                <link rel="alternate" type="text/xml" title="XML Full-Text" href="http://www.mdpi.com/1420-3049/21/2/189/xml">
        <meta name="fulltext_xml" content="http://www.mdpi.com/1420-3049/21/2/189/xml">
    <meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@MDPIOpenAccess" /><meta name="twitter:image" content="http://img.mdpi.org/img/journals/molecules-logo-sq.png?97552ead561a93b2" /><meta property="fb:app_id" content="131189377574"/><meta property="og:site_name" content="MDPI"/>
 	<meta property="og:type" content="article"/>
 	<meta property="article:publisher" content="https://www.facebook.com/MDPIOpenAccessPublishing"/>
 	<meta property="og:url" content="http://www.mdpi.com/1420-3049/21/2/189" />
 	<meta property="og:title" content="Design, Synthesis and Anticancer Evaluation of Novel Quinazoline-Sulfonamide Hybrids" />
	<meta property="og:description" content="By combining the structural features of quinazoline and sulfonamides, novel hybrid compounds 2–21 were synthesized using a simple and convenient method. Evaluation of these compounds against different cell lines identified compounds 7 and 17 as most active anticancer agents as they showed effectiveness on the four tested cell lines. The anticancer screening results of the tested compounds provides an encouraging framework that could lead to the development of potent new anticancer agents." /><meta property="og:image" content="http://img.mdpi.org/img/journals/molecules-logo-sq.png?97552ead561a93b2" />





                <link rel="alternate" type="application/rss+xml" title="MDPI Publishing - Latest articles" href="http://www.mdpi.com/rss">
        		  <script type="text/x-mathjax-config">
    MathJax.Hub.processSectionDelay = 0;
      MathJax.Hub.Config({
        menuSettings: {
          CHTMLpreview: false
        },
        "CHTML-preview":{
          disabled: true
        },
        "HTML-CSS": {
          availableFonts: ["TeX"],
          preferredFonts: "TeX",
          webFont:"TeX",
          imageFont:"TeX",
          undefinedFamily:"'Arial Unicode MS',serif"
        },
        "TeX": {
          extensions: ["noErrors.js"],
          noErrors: {
            inlineDelimiters: ["",""],
            multiLine: true,
            style: {
              "font-size":   "90%",
              "text-align":  "left",
              "color":       "black",
              "padding":     "1px 3px",
              "border":      "1px solid"
            }
          }
        }
      });
    </script>

    <script type="text/javascript" src="http://img.mdpi.org/bundles/mathjax/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
        <meta name="google-site-verification" content="PxTlsg7z2S00aHroktQd57fxygEjMiNHydKn3txhvwY">
        <!--[if lt IE 9]>
        <script src="//html5shiv.googlecode.com/svn/trunk/html5.js"></script>
        <![endif]-->

    </head>
    <body>
    			  							

		<div class="direction direction_right" id="small_right" style="border-right-width: 0px; padding:0;"><i class="fa fa-caret-right fa-2x" style="float: right; margin: 27px 5px 0px 0px"></i></div>
	<div class="big_direction direction_right" id="big_right" style="border-right-width: 0px;  padding: 0 0 0 1em;">
		<i class="fa fa-caret-right fa-2x" style="margin: 27px 5px 0px 0px; float:right"></i>
		<div style="text-align: right; position:relative; margin: 0 1.7em 0 0">
									Next Article in Journal<br>
				<div><a href="http://www.mdpi.com/1420-3049/21/2/186">Peltomexicanin, a Peltogynoid Quinone Methide from <i>Peltogyne Mexicana</i> Martínez Purple Heartwood</a></div>
					 		 		 	</div>
	</div>
	
		<div class="direction" id="small_left" style="border-left-width: 0px"><i class="fa fa-caret-left fa-2x" style="margin: 27px 4px;"></i></div>
	<div class="big_direction" id="big_left" style="border-left-width: 0px;">
		<i class="fa fa-caret-left fa-2x" style="float: left; margin: 27px 4px"></i>
		<div>
									Previous Article in Journal<br>
				<div><a href="http://www.mdpi.com/1420-3049/21/2/188">Two New Oleanane-Type Saponins with Anti-Proliferative Activity from <i>Camellia oleifera</i> Abel. Seed Cake</a></div>
					 			 	 	</div>
	</div>
		<div style="clear: both;"/>
        <div id="container">
            <div id="stripeleft" style="background:url(http://img.mdpi.org/img/design/stripe_left.png?7a19bc8a135e08fa) no-repeat top left">
                <div id="striperight" style="background:url(http://img.mdpi.org/img/design/stripe_right.png?a2355fb262ff8e6e) no-repeat top right">
                    <div id="topmenu" style="padding:0;">
                    <div id="topmenu_container" style="padding-top:9px;">
                            <ul style="padding:0 1.5em;" class="subMenu">
                                <li class="user-quick-cmd">
                                                                            <a href="http://susy.mdpi.com/user/manuscripts/upload?journal=molecules">Submit to Molecules</a>
                                                                            <a href="/user/login">Login</a>
                                        <a href="/user/register">Register</a>
                                                                    </li>
                                <li><a href="/">MDPI</a></li>
                                <li><a href="/about/journals">Journals A-Z</a></li>
                                <li><a href="/guidelines">Information & Guidelines</a>
							    	<ul>
							        	<li><a href="/authors">For Authors</a></li>
							        	<li><a href="/reviewers">For Reviewers</a></li>
		                                <li><a href="/editors">For Editors</a></li>
		                                <li><a href="/librarians">For Librarians</a></li>
		                                <li><a href="/xml">For Publishers</a></li>
		                                <li><a href="/about/openaccess">Open Access Policy</a></li>
							        </ul>
							    </li>
                                <li><a href="/about">About</a></li>
                                <li><a href="/editorial_process">Editorial Process</a></li>
                                                            </ul>
                            </div>
                    </div><div id="search">
                    	<table class="container" cellspacing="0" cellpadding="0">
                            <tr>
                                <td class="logo">
                                    <a href="/journal/molecules"><img src="http://img.mdpi.org/img/journals/molecules-logo.png?97552ead561a93b2" alt="molecules-logo" title="molecules Open Access Journals" style="max-height:70px; max-width:220px;"></a>
                                </td>
								
																																	
                                <td class="form"><!-- search form -->
    <form  action="/search" method="get" id="searchBar">
      <table>
        <tr><td>
        <table class="search_form" cellspacing="0" cellpadding="2">
            <tr>
                <td><div class="lb">Title / Keyword</div></td>
                <td class="field"><input type="text" id="q" tabindex="1" name="q" value="" /></td>
                <td><div class="lb">Journal</div></td>
                <td class="field"><select id="journal" tabindex="4" name="journal">
                        <option value="">all</option>
                         
                            <option value="actuators">Actuators</option>
                         
                            <option value="admsci">Administrative Sciences</option>
                         
                            <option value="aerospace">Aerospace</option>
                         
                            <option value="agriculture">Agriculture</option>
                         
                            <option value="agronomy">Agronomy</option>
                         
                            <option value="algorithms">Algorithms</option>
                         
                            <option value="animals">Animals</option>
                         
                            <option value="antibiotics">Antibiotics</option>
                         
                            <option value="antibodies">Antibodies</option>
                         
                            <option value="antioxidants">Antioxidants</option>
                         
                            <option value="applsci">Applied Sciences</option>
                         
                            <option value="arts">Arts</option>
                         
                            <option value="atmosphere">Atmosphere</option>
                         
                            <option value="atoms">Atoms</option>
                         
                            <option value="axioms">Axioms</option>
                         
                            <option value="batteries">Batteries</option>
                         
                            <option value="behavsci">Behavioral Sciences</option>
                         
                            <option value="beverages">Beverages</option>
                         
                            <option value="bioengineering">Bioengineering</option>
                         
                            <option value="biology">Biology</option>
                         
                            <option value="biomedicines">Biomedicines</option>
                         
                            <option value="biomimetics">Biomimetics</option>
                         
                            <option value="biomolecules">Biomolecules</option>
                         
                            <option value="biosensors">Biosensors</option>
                         
                            <option value="brainsci">Brain Sciences</option>
                         
                            <option value="buildings">Buildings</option>
                         
                            <option value="carbon">C</option>
                         
                            <option value="cancers">Cancers</option>
                         
                            <option value="catalysts">Catalysts</option>
                         
                            <option value="cells">Cells</option>
                         
                            <option value="challenges">Challenges</option>
                         
                            <option value="chemosensors">Chemosensors</option>
                         
                            <option value="children">Children</option>
                         
                            <option value="chromatography">Chromatography</option>
                         
                            <option value="climate">Climate</option>
                         
                            <option value="coatings">Coatings</option>
                         
                            <option value="computation">Computation</option>
                         
                            <option value="computers">Computers</option>
                         
                            <option value="condensedmatter">Condensed Matter</option>
                         
                            <option value="cosmetics">Cosmetics</option>
                         
                            <option value="cryptography">Cryptography</option>
                         
                            <option value="crystals">Crystals</option>
                         
                            <option value="data">Data</option>
                         
                            <option value="dentistry">Dentistry Journal</option>
                         
                            <option value="diagnostics">Diagnostics</option>
                         
                            <option value="diseases">Diseases</option>
                         
                            <option value="diversity">Diversity</option>
                         
                            <option value="econometrics">Econometrics</option>
                         
                            <option value="economies">Economies</option>
                         
                            <option value="education">Education Sciences</option>
                         
                            <option value="electronics">Electronics</option>
                         
                            <option value="energies">Energies</option>
                         
                            <option value="entropy">Entropy</option>
                         
                            <option value="environments">Environments</option>
                         
                            <option value="epigenomes">Epigenomes</option>
                         
                            <option value="fermentation">Fermentation</option>
                         
                            <option value="fibers">Fibers</option>
                         
                            <option value="fishes">Fishes</option>
                         
                            <option value="fluids">Fluids</option>
                         
                            <option value="foods">Foods</option>
                         
                            <option value="forests">Forests</option>
                         
                            <option value="futureinternet">Future Internet</option>
                         
                            <option value="galaxies">Galaxies</option>
                         
                            <option value="games">Games</option>
                         
                            <option value="gels">Gels</option>
                         
                            <option value="genealogy">Genealogy</option>
                         
                            <option value="genes">Genes</option>
                         
                            <option value="geosciences">Geosciences</option>
                         
                            <option value="geriatrics">Geriatrics</option>
                         
                            <option value="healthcare">Healthcare</option>
                         
                            <option value="horticulturae">Horticulturae</option>
                         
                            <option value="humanities">Humanities</option>
                         
                            <option value="hydrology">Hydrology</option>
                         
                            <option value="informatics">Informatics</option>
                         
                            <option value="information">Information</option>
                         
                            <option value="infrastructures">Infrastructures</option>
                         
                            <option value="inorganics">Inorganics</option>
                         
                            <option value="insects">Insects</option>
                         
                            <option value="ijerph">IJERPH</option>
                         
                            <option value="ijfs">IJFS</option>
                         
                            <option value="ijms">IJMS</option>
                         
                            <option value="neonatalscreening">IJNS</option>
                         
                            <option value="inventions">Inventions</option>
                         
                            <option value="ijgi">IJGI</option>
                         
                            <option value="jcdd">JCDD</option>
                         
                            <option value="jcm">JCM</option>
                         
                            <option value="jdb">JDB</option>
                         
                            <option value="jfb">JFB</option>
                         
                            <option value="jfmk">JFMK</option>
                         
                            <option value="jof">JoF</option>
                         
                            <option value="jimaging">J. Imaging</option>
                         
                            <option value="jintelligence">J. Intell.</option>
                         
                            <option value="jlpea">JLPEA</option>
                         
                            <option value="jmse">JMSE</option>
                         
                            <option value="jpm">JPM</option>
                         
                            <option value="jrfm">JRFM</option>
                         
                            <option value="jsan">JSAN</option>
                         
                            <option value="land">Land</option>
                         
                            <option value="languages">Languages</option>
                         
                            <option value="laws">Laws</option>
                         
                            <option value="life">Life</option>
                         
                            <option value="lubricants">Lubricants</option>
                         
                            <option value="machines">Machines</option>
                         
                            <option value="magnetochemistry">Magnetochemistry</option>
                         
                            <option value="marinedrugs">Marine Drugs</option>
                         
                            <option value="materials">Materials</option>
                         
                            <option value="mca">MCA</option>
                         
                            <option value="mathematics">Mathematics</option>
                         
                            <option value="medsci">Medical Sciences</option>
                         
                            <option value="medicines">Medicines</option>
                         
                            <option value="membranes">Membranes</option>
                         
                            <option value="metabolites">Metabolites</option>
                         
                            <option value="metals">Metals</option>
                         
                            <option value="microarrays">Microarrays</option>
                         
                            <option value="micromachines">Micromachines</option>
                         
                            <option value="microorganisms">Microorganisms</option>
                         
                            <option value="minerals">Minerals</option>
                         
                            <option value="molbank">Molbank</option>
                         
                            <option value="molecules" selected="selected">Molecules</option>
                         
                            <option value="mti">MTI</option>
                         
                            <option value="nanomaterials">Nanomaterials</option>
                         
                            <option value="ncrna">ncRNA</option>
                         
                            <option value="nutrients">Nutrients</option>
                         
                            <option value="pathogens">Pathogens</option>
                         
                            <option value="pharmaceuticals">Pharmaceuticals</option>
                         
                            <option value="pharmaceutics">Pharmaceutics</option>
                         
                            <option value="pharmacy">Pharmacy</option>
                         
                            <option value="philosophies">Philosophies</option>
                         
                            <option value="photonics">Photonics</option>
                         
                            <option value="plants">Plants</option>
                         
                            <option value="polymers">Polymers</option>
                         
                            <option value="processes">Processes</option>
                         
                            <option value="proteomes">Proteomes</option>
                         
                            <option value="publications">Publications</option>
                         
                            <option value="recycling">Recycling</option>
                         
                            <option value="religions">Religions</option>
                         
                            <option value="remotesensing">Remote Sensing</option>
                         
                            <option value="resources">Resources</option>
                         
                            <option value="risks">Risks</option>
                         
                            <option value="robotics">Robotics</option>
                         
                            <option value="safety">Safety</option>
                         
                            <option value="sensors">Sensors</option>
                         
                            <option value="separations">Separations</option>
                         
                            <option value="sinusitis">Sinusitis</option>
                         
                            <option value="socsci">Social Sciences</option>
                         
                            <option value="societies">Societies</option>
                         
                            <option value="sports">Sports</option>
                         
                            <option value="sustainability">Sustainability</option>
                         
                            <option value="symmetry">Symmetry</option>
                         
                            <option value="systems">Systems</option>
                         
                            <option value="technologies">Technologies</option>
                         
                            <option value="toxics">Toxics</option>
                         
                            <option value="toxins">Toxins</option>
                         
                            <option value="tropicalmed">TropicalMed</option>
                         
                            <option value="universe">Universe</option>
                         
                            <option value="urbansci">Urban Science</option>
                         
                            <option value="vaccines">Vaccines</option>
                         
                            <option value="vetsci">Veterinary Sciences</option>
                         
                            <option value="viruses">Viruses</option>
                         
                            <option value="vision">Vision</option>
                         
                            <option value="water">Water</option>
                                        </select></td>
				<td style="text-align: center;"><div class="lb"><a href="/search" style="color: inherit; border-bottom: 1px dotted;">Advanced</a></div></td>
				            </tr>
            <tr>
                <td><div class="lb">Author</div></td>
                <td class="field"><input type="text" id="authors" tabindex="2" name="authors" value="" /></td>
                <td><div class="lb">Section</div></td>
                <td class="field"><select id="section" tabindex="5" name="section"><option value="">---</option></select></td>
									<td class="field" colspan="2"><input type="submit" id="search" value="Search" class="searchButton" tabindex="12" name="search" style="margin: 0 0 0 0; float:right;"></td>
							</tr>
            <tr>
                <td><div class="lb">Article Type</div></td>
                <td class="field"><select id="article_type" tabindex="3" name="article_type"><option value="">all</option>
                                                                            <option value="addendum">Addendum</option>
                                                    <option value="research-article">Article</option>
                                                    <option value="book-review">Book Review</option>
                                                    <option value="case-report">Case Report</option>
                                                    <option value="article-commentary">Comment</option>
                                                    <option value="commentary">Commentary</option>
                                                    <option value="rapid-communication">Communication</option>
                                                    <option value="concept-paper">Concept Paper</option>
                                                    <option value="conference-report">Conference Report</option>
                                                    <option value="correction">Correction</option>
                                                    <option value="creative">Creative</option>
                                                    <option value="data-descriptor">Data Descriptor</option>
                                                    <option value="discussion">Discussion</option>
                                                    <option value="editorial">Editorial</option>
                                                    <option value="erratum">Erratum</option>
                                                    <option value="essay">Essay</option>
                                                    <option value="expression-of-concern">Expression of Concern</option>
                                                    <option value="interesting-image">Interesting Images</option>
                                                    <option value="letter">Letter</option>
                                                    <option value="books-received">New Book Received</option>
                                                    <option value="obituary">Obituary</option>
                                                    <option value="opinion">Opinion</option>
                                                    <option value="project-report">Project Report</option>
                                                    <option value="reply">Reply</option>
                                                    <option value="retraction">Retraction</option>
                                                    <option value="review-article">Review</option>
                                                    <option value="note">Short Note</option>
                                                    <option value="technical-note">Technical Note</option>
                                        </select></td>
                <td><div class="lb">Special Issue</div></td>
                <td class="field"><select id="special_issue" tabindex="6" name="special_issue"><option value="">---</option></select></td>
                <td class="field" colspan="2"><input tabindex="9" type="reset" value="Clear" id="clear" class="submit" style="margin: 0 0 0 0; float:right;"></td>
                            </tr>
        </table></td> 
								
																<td style="width: 100%">

        

<div style="width: 100%; text-align: right;">
    <div style="margin-right: 0.5em; width: 130px; display: inline-block;">
        <div class="jif_parent" style="float:left"><div class="jif_floater">
                <a href="/about/anniversary20"><img width="75px" height="75px" src="http://img.mdpi.org/bundles/mdpimain/img/anniversary_logo_150px.png" style="vertical-align:middle;" alt="logo"></a>
            </div>
        </div>
        
        <div class="jif_parent">
                <div class="jif_floater">
                    <div class="jif_label">                        
                            <a href="/journal/molecules/stats" style="color: inherit; text-decoration: none;">                        
                                <span class="jif_text">IMPACT<br />FACTOR</span><br />
                                <span class="jif_number">2.465</span>
                            </a>
                                            </div>
                </div>
            </div>
            </div>
</div>
</td>

</tr></table>

</form></td>                            </tr>
                        </table>
                    </div>

                    <div id="main">
  <div id="leftcol">

	<div style="margin:0 0.9em 1em 0.6em; padding:0; background-color:#007F7F; border-bottom:0.5em solid #99CCCC;">
	<ul class="menu-journal">
		<li>
			<a style="color:#FFFFFF; text-decoration:underline;" href="/journal/molecules"><em>Molecules</em></a>
		</li>
		<li>
			<a style="color:#FFFFFF; text-decoration:underline;" href="/1420-3049/21/2">
				Volume 21, Issue 2
			</a>
		</li>
	</ul>
	</div>

                    <a href="/1420-3049/21/2">
                <img style="width: 164px;margin:0 0.9em 1em 0.6em;" src="http://img.mdpi.org/data/covers/molecules/cover-molecules-v21-i2.png" alt="Issue 2 (February) cover image"></img>
            </a>
                        
        
	        <div class="menu-caption"><span>Article Versions</span></div>
        <ul class="menu">

            <li><a href="http://www.mdpi.com/1420-3049/21/2/189">Abstract</a></li>

                    <li><a href="http://www.mdpi.com/1420-3049/21/2/189/htm">Full-Text HTML</a></li>
        
                    <li><a href="http://www.mdpi.com/1420-3049/21/2/189/pdf" onclick="javascript:urchinTracker('http://www.mdpi.com/1420-3049/21/2/189/pdf');">Full-Text PDF</a> <span class="size">[793 KB]</span></li>
        
        
                    <li><a href="http://www.mdpi.com/1420-3049/21/2/189/xml" onclick="javascript:urchinTracker('http://www.mdpi.com/1420-3049/21/2/189/xml');">Full-Text XML</a></li>
        
                    <li><a href="http://www.mdpi.com/1420-3049/21/2/189/notes" onclick="javascript:urchinTracker('http://www.mdpi.com/1420-3049/21/2/189/notes');">Article Versions Notes</a></li>
        
        								   <li><a id=supplement_link href="http://www.mdpi.com/1420-3049/21/2/189#supplementary">Supplementary material</a></li>
		      	           </ul>
	
  <div class="menu-caption"><span>Related Info</span></div>
	<ul class="menu">
        		<li><a id=stats_link href="http://www.mdpi.com/1420-3049/21/2/189#stats">Article Statistics</a></li>		<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez/26861266" target="_blank">PubMed/Medline</a></li>		<li><a href="http://scholar.google.com/scholar?q=Design, Synthesis and Anticancer Evaluation of Novel Quinazoline-Sulfonamide Hybrids" target="_blank">Google Scholar</a></li>
		<li><a href="http://www.mdpi.com/1420-3049/21/2/189/reprints">Order Reprints</a></li>
	</ul>

  <div class="menu-caption"><span>More by Authors</span></div>
	<ul class="menu">
		<li><a class="expand">[+] on DOAJ</a></li>
          <div id="AuthorDOAJExpand" style="display:none;">
            <ul class="submenu">
                           <li>
            <a href="http://doaj.org/search?source=%7B&quot;query&quot;:%7B&quot;query_string&quot;:%7B&quot;query&quot;:&quot;Mostafa+M.+Ghorab&quot;,&quot;default_operator&quot;:&quot;AND&quot;%7D%7D%7D" target="_blank">Ghorab, MM.</a>
        </li>
            <li>
            <a href="http://doaj.org/search?source=%7B&quot;query&quot;:%7B&quot;query_string&quot;:%7B&quot;query&quot;:&quot;Mansour+S.+Alsaid&quot;,&quot;default_operator&quot;:&quot;AND&quot;%7D%7D%7D" target="_blank">Alsaid, MS.</a>
        </li>
            <li>
            <a href="http://doaj.org/search?source=%7B&quot;query&quot;:%7B&quot;query_string&quot;:%7B&quot;query&quot;:&quot;Mohammed+S.+Al-Dosari&quot;,&quot;default_operator&quot;:&quot;AND&quot;%7D%7D%7D" target="_blank">Al-Dosari, MS.</a>
        </li>
            <li>
            <a href="http://doaj.org/search?source=%7B&quot;query&quot;:%7B&quot;query_string&quot;:%7B&quot;query&quot;:&quot;Marwa+G.+El-Gazzar&quot;,&quot;default_operator&quot;:&quot;AND&quot;%7D%7D%7D" target="_blank">El-Gazzar, MG.</a>
        </li>
            <li>
            <a href="http://doaj.org/search?source=%7B&quot;query&quot;:%7B&quot;query_string&quot;:%7B&quot;query&quot;:&quot;Mohammad+K.+Parvez&quot;,&quot;default_operator&quot;:&quot;AND&quot;%7D%7D%7D" target="_blank">Parvez, MK.</a>
        </li>
    
			</ul>
          </div>
		<li><a class="expand">[+] on Google Scholar</a></li>
		<div id="AuthorGoogleExpand" style="display:none;">
            <ul class="submenu">
                           <li>
            <a href="http://scholar.google.com/scholar?q=Mostafa+M.+Ghorab" target="_blank">Ghorab, MM.</a>
        </li>
            <li>
            <a href="http://scholar.google.com/scholar?q=Mansour+S.+Alsaid" target="_blank">Alsaid, MS.</a>
        </li>
            <li>
            <a href="http://scholar.google.com/scholar?q=Mohammed+S.+Al-Dosari" target="_blank">Al-Dosari, MS.</a>
        </li>
            <li>
            <a href="http://scholar.google.com/scholar?q=Marwa+G.+El-Gazzar" target="_blank">El-Gazzar, MG.</a>
        </li>
            <li>
            <a href="http://scholar.google.com/scholar?q=Mohammad+K.+Parvez" target="_blank">Parvez, MK.</a>
        </li>
    
			</ul>
          </div>

	<li><a class="expand">[+] on PubMed</a></li>
          <div id="AuthorPubMedExpand" style="display:none;">
            <ul class="submenu">
                           <li>
            <a href="http://www.pubmed.com/?cmd=Search&amp;term=Mostafa+M.+Ghorab" target="_blank">Ghorab, MM.</a>
        </li>
            <li>
            <a href="http://www.pubmed.com/?cmd=Search&amp;term=Mansour+S.+Alsaid" target="_blank">Alsaid, MS.</a>
        </li>
            <li>
            <a href="http://www.pubmed.com/?cmd=Search&amp;term=Mohammed+S.+Al-Dosari" target="_blank">Al-Dosari, MS.</a>
        </li>
            <li>
            <a href="http://www.pubmed.com/?cmd=Search&amp;term=Marwa+G.+El-Gazzar" target="_blank">El-Gazzar, MG.</a>
        </li>
            <li>
            <a href="http://www.pubmed.com/?cmd=Search&amp;term=Mohammad+K.+Parvez" target="_blank">Parvez, MK.</a>
        </li>
    
			</ul>
          </div>
	</ul>
  <div class="menu-caption"><span>Share This Article</span></div>
	<ul class="menu">
		<li><a href="http://twitter.com/home?status=%23mdpimolecules+Design%2C+Synthesis+and+Anticancer+Evaluation+of+Novel+Quinazoline-Sulfonamide+Hybrids+http%3A%2F%2Fwww.mdpi.com%2F1420-3049%2F21%2F2%2F189++%40Molecules_MDPI" onclick="windowOpen(this.href,600,800); return false"><img border="0" src="http://img.mdpi.org/img/icons/twitter_new.png?fd8dab924a348c64" width="16" height="16" class="textmiddle">&nbsp;Twitter</a></li>
		<li><a href="http://www.facebook.com/sharer.php?u=http://www.mdpi.com/1420-3049/21/2/189" target="_blank"><img border="0" src="http://img.mdpi.org/img/icons/facebook_new.png?2800a8d3985cf91d" width="16" height="16" class="textmiddle">&nbsp;Facebook</a></li>
		<li><a href="http://www.mendeley.com/import/?url=http://www.mdpi.com/1420-3049/21/2/189" target="_blank"><img border="0" src="http://img.mdpi.org/img/icons/mendeley_new.png?e4486db70babb78e" width="16" height="16" class="textmiddle">&nbsp;Mendeley</a></li>
		<li><a href="http://www.citeulike.org/posturl?url=http://www.mdpi.com/1420-3049/21/2/189" target="_blank"><img border="0" src="http://img.mdpi.org/img/icons/citeulike_new.jpg?46b2647c72fd5d8b" width="16" height="16" class="textmiddle">&nbsp;CiteULike</a></li>
	</ul>
		
            <div class="menu-caption" id="html-quick-links-title"> <span>Quick Links</span> </div>
	</div>
                        <div class="rightcol"></div>                        <link href="/assets/css/font-awesome.min.css" rel="stylesheet"><div id="maincol" style="position: relative;">
      
<ul class="menu html-nav" data-prev-node="#html-quick-links-title">
</ul>
<article>
  <div class='html-front'>
  <span class="html-oa-logo">
    <a href="http://www.mdpi.com/about/openaccess">
      Open Access
      <span class="html-oa-logo-extended" style="margin: 2px 0 0 -3px">This article is
        <ul>
          <li>freely available</li>
          <li>re-usable</li>
        </ul>
      </span>
    </a>
  </span>
  <div class="html-art-header">
    <p>
      <i>Molecules</i>
      <b>2016</b>,
      <i>21</i>(2),
      189;
      doi:<a href="http://dx.doi.org/10.3390/molecules21020189" target="_blank">10.3390/molecules21020189</a>
    </p>
  </div>

  <div class="html-art-type">
    Article
  </div>

  <div id="html-article-title">Design, Synthesis and Anticancer Evaluation of Novel Quinazoline-Sulfonamide Hybrids</div>

  <div class="html-author-group">
    Mostafa M. Ghorab <sup><span data-rid='af1-molecules-21-00189'>1</span></sup><sup>,</sup><sup><span data-rid='af2-molecules-21-00189'>2</span></sup><sup>,</sup><span data-rid='c1-molecules-21-00189'>*</span>,
    
    Mansour S. Alsaid <sup><span data-rid='af1-molecules-21-00189'>1</span></sup>,
    
    Mohammed S. Al-Dosari <sup><span data-rid='af1-molecules-21-00189'>1</span></sup>,
    
    Marwa G. El-Gazzar <sup><span data-rid='af2-molecules-21-00189'>2</span></sup>
    and
    Mohammad K. Parvez <sup><span data-rid='af1-molecules-21-00189'>1</span></sup>
    
  </div>

  <div class="html-aff-group">
    <div class="html-aff" id=af1-molecules-21-00189 >
      <div class="html-label" >
        <sup data-label='1'>1</sup>
      </div>
      <div class="html-content" >Department of Pharmacognosy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia</div>
    </div>
    <div class="html-aff" id=af2-molecules-21-00189 >
      <div class="html-label" >
        <sup data-label='2'>2</sup>
      </div>
      <div class="html-content" >Department of Drug Radiation Research, National Center for Radiation Research and Technology, Atomic Energy Authority, P.O. Box 29, Nasr City, Cairo 11371, Egypt</div>
    </div>
  </div>

  <div class="html-notes">
    <div class="html-note" id=c1-molecules-21-00189>
      <div class="html-label">
        *
      </div>
      <div class="html-content">Correspondence: Tel.: +966-53-4292-860; Fax: +966-1-4670-560</div>
    </div>
  </div>


  <div class="html-external_editor">
    Academic Editors:
      Jean Jacques Vanden Eynde
      and
      Annie Mayence
      
  </div>

  <div class="html-history">
    Received: 18 December 2015 / Accepted: 29 January 2016 / Published: 4 February 2016
  </div>

  <section class="html-abstract" id="html-abstract">

      <h2 id="html-abstract-title">Abstract</h2><b>:</b>
      By combining the structural features of quinazoline and sulfonamides, novel hybrid compounds <b>2</b>–<b>21</b> were synthesized using a simple and convenient method. Evaluation of these compounds against different cell lines identified compounds <b>7</b> and <b>17</b> as most active anticancer agents as they showed effectiveness on the four tested cell lines. The anticancer screening results of the tested compounds provides an encouraging framework that could lead to the development of potent new anticancer agents.

  </section>

  <div id="html-keywords">
    <div class='html-gwd-group'><div id='html-keywords-title'>Keywords:</div>
    synthesis; quinazoline; sulfonamides; anticancer activity</div>

  </div>


</div>
  <div class="html-body">
    <section id='sec1-molecules-21-00189' type='intro'><h2 data-nested='1'>  1. Introduction</h2><div class='html-p'>Cancer continues to be a leading health problem in developed as well as developing countries. It has become the number one killer due to various worldwide factors [<a href="#B1-molecules-21-00189" class="html-bibr">1</a>,<a href="#B2-molecules-21-00189" class="html-bibr">2</a>,<a href="#B3-molecules-21-00189" class="html-bibr">3</a>,<a href="#B4-molecules-21-00189" class="html-bibr">4</a>,<a href="#B5-molecules-21-00189" class="html-bibr">5</a>]. This enormous incidence of cancer has increased the urgency of the search for the latest, safer and efficacious anticancer agents, aiming at the prevention or the cure of this illness [<a href="#B6-molecules-21-00189" class="html-bibr">6</a>,<a href="#B7-molecules-21-00189" class="html-bibr">7</a>,<a href="#B8-molecules-21-00189" class="html-bibr">8</a>]. In the efforts to identify various chemical substances which may serve as leads for designing novel anticancer agents, nitrogen- and sulfur- containing heterocycles are of particular interest [<a href="#B9-molecules-21-00189" class="html-bibr">9</a>,<a href="#B10-molecules-21-00189" class="html-bibr">10</a>,<a href="#B11-molecules-21-00189" class="html-bibr">11</a>]. Quinazoline and sulfonamide moieties have been identified as classes of cancer chemotherapeutic agents with significant therapeutic efficacy against solid tumors. In recent years, quinazolines, as an important pharmacophore, have emerged as a versatile template for inhibition of a diverse range of receptor tyrosine kinases [<a href="#B12-molecules-21-00189" class="html-bibr">12</a>,<a href="#B13-molecules-21-00189" class="html-bibr">13</a>,<a href="#B14-molecules-21-00189" class="html-bibr">14</a>,<a href="#B15-molecules-21-00189" class="html-bibr">15</a>,<a href="#B16-molecules-21-00189" class="html-bibr">16</a>]. The most widely studied of these is the epidermal growth factor receptor (EGFR), with the small-molecule inhibitor gefitinib being the first quinazoline derivative to be approved for the treatment of Non-Small Cell Lung Cancer [<a href="#B17-molecules-21-00189" class="html-bibr">17</a>,<a href="#B18-molecules-21-00189" class="html-bibr">18</a>,<a href="#B19-molecules-21-00189" class="html-bibr">19</a>,<a href="#B20-molecules-21-00189" class="html-bibr">20</a>,<a href="#B21-molecules-21-00189" class="html-bibr">21</a>]. Subsequent research aimed at further exploration of the SAR of this novel template has led to discovery of highly selective compounds that target EGFR such as erlotinib, lapatinib, canertinib and vandetanib [<a href="#B22-molecules-21-00189" class="html-bibr">22</a>,<a href="#B23-molecules-21-00189" class="html-bibr">23</a>,<a href="#B24-molecules-21-00189" class="html-bibr">24</a>] (<a href="#molecules-21-00189-f001" class="html-fig">Figure 1</a>). These compounds act via competing with ATP for binding at the catalytic domain of tyrosine kinase. Later on, a great structural variety of compounds of structurally diverse classes have proved to be highly potent and selective ATP-competitive inhibitors [<a href="#B25-molecules-21-00189" class="html-bibr">25</a>,<a href="#B26-molecules-21-00189" class="html-bibr">26</a>,<a href="#B27-molecules-21-00189" class="html-bibr">27</a>,<a href="#B28-molecules-21-00189" class="html-bibr">28</a>]. Based on the good performances of quinazoline derivatives in anticancer applications, the development of novel quinazoline derivatives as anticancer drugs is a promising field. </div><div class='html-p'>Varied biological activities have been attributed to sulfonamide compounds, including carbonic anhydrase inhibition, antitumoral, antimalarial and antimicrobial activities [<a href="#B29-molecules-21-00189" class="html-bibr">29</a>,<a href="#B30-molecules-21-00189" class="html-bibr">30</a>,<a href="#B31-molecules-21-00189" class="html-bibr">31</a>]. In the design of new drugs, the development of hybrid molecules through the combination of different pharmacophores may lead to compounds with interesting biological profiles [<a href="#B32-molecules-21-00189" class="html-bibr">32</a>]. In view of the abovementioned knowledge about different pharmacophores and in continuation of our research programme [<a href="#B33-molecules-21-00189" class="html-bibr">33</a>,<a href="#B34-molecules-21-00189" class="html-bibr">34</a>,<a href="#B35-molecules-21-00189" class="html-bibr">35</a>,<a href="#B36-molecules-21-00189" class="html-bibr">36</a>,<a href="#B37-molecules-21-00189" class="html-bibr">37</a>,<a href="#B38-molecules-21-00189" class="html-bibr">38</a>,<a href="#B39-molecules-21-00189" class="html-bibr">39</a>,<a href="#B40-molecules-21-00189" class="html-bibr">40</a>,<a href="#B41-molecules-21-00189" class="html-bibr">41</a>,<a href="#B42-molecules-21-00189" class="html-bibr">42</a>,<a href="#B43-molecules-21-00189" class="html-bibr">43</a>,<a href="#B44-molecules-21-00189" class="html-bibr">44</a>,<a href="#B45-molecules-21-00189" class="html-bibr">45</a>], we have now synthesized quinazoline-sulfonamide hybrids to obtain a single molecular framework incorporating both moieties. These hybrid molecules consist of a planar heterocyclic ring (quinazoline) with a hydrophobic phenyl ring at position-2 as a central core that can act as a scaffold to carry a functionalized branch at position-4, in such a way to accommodate a sulfonamide moiety (<a href="#molecules-21-00189-f002" class="html-fig">Figure 2</a>). Introduction of the benzensulfonamide amino group at position-4 will add a new hydrogen bond donor, a very much needed characteristic for the desired activity [<a href="#B46-molecules-21-00189" class="html-bibr">46</a>]. These compounds were then screened for their <span class='html-italic'>in vitro</span> anticancer activity against various cell lines.</div><div class="html-fig-wrap" id="molecules-21-00189-f001">
  <div class='html-fig_img'>
    <div class="html-figpopup html-figpopup-link" href="#fig_body_display_molecules-21-00189-f001">
      <img alt="Molecules 21 00189 g001 1024" data-large="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g001-1024.png" data-original="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g001.png" src="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g001-1024.png" />
      <a class="html-expand html-figpopup" href="#fig_body_display_molecules-21-00189-f001"></a>
    </div>

  </div>
  <div class="html-fig_description">
    <b>Figure 1.</b>
      EGFR-tyrosine kinase inhibitors.
<!--     <p><a class="html-figpopup" href="#fig_body_display_molecules-21-00189-f001">
      Click here to enlarge figure
    </a></p> -->

  </div>
</div>
<div class="html-fig_show  mfp-hide" id ="fig_body_display_molecules-21-00189-f001" >
  <div class="html-caption" > <b>Figure 1.</b>
      EGFR-tyrosine kinase inhibitors.</div>
  <div class="html-img"><img alt="Molecules 21 00189 g001 1024" data-large="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g001-1024.png" data-original="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g001.png" src="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g001-1024.png" /></div>
</div><div class="html-fig-wrap" id="molecules-21-00189-f002">
  <div class='html-fig_img'>
    <div class="html-figpopup html-figpopup-link" href="#fig_body_display_molecules-21-00189-f002">
      <img alt="Molecules 21 00189 g002 1024" data-large="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g002-1024.png" data-original="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g002.png" src="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g002-1024.png" />
      <a class="html-expand html-figpopup" href="#fig_body_display_molecules-21-00189-f002"></a>
    </div>

  </div>
  <div class="html-fig_description">
    <b>Figure 2.</b>
      The designed quinazoline-sulfonamide hybrids.
<!--     <p><a class="html-figpopup" href="#fig_body_display_molecules-21-00189-f002">
      Click here to enlarge figure
    </a></p> -->

  </div>
</div>
<div class="html-fig_show  mfp-hide" id ="fig_body_display_molecules-21-00189-f002" >
  <div class="html-caption" > <b>Figure 2.</b>
      The designed quinazoline-sulfonamide hybrids.</div>
  <div class="html-img"><img alt="Molecules 21 00189 g002 1024" data-large="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g002-1024.png" data-original="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g002.png" src="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g002-1024.png" /></div>
</div></section><section id='sec2-molecules-21-00189' type='results'><h2 data-nested='1'>  2. Results and Discussion</h2><section id='sec2dot1-molecules-21-00189' type=''><h4 class=html-italic data-nested='2'>  2.1. Chemistry</h4><div class='html-p'>The aim of this work was to design and synthesize novel quinazoline-sulfonamide hybrids to evaluate their anticancer activity. Thus, interaction of 4-chloro-2-phenylquinazoline (<b>1</b>) with several sulfonamides in dry <span class='html-italic'>N</span>,<span class='html-italic'>N</span>-dimethylformamide afforded the corresponding quinazoline-sulfonamide derivatives <b>2</b>–<b>18</b> (<a href="#molecules-21-00189-f003" class="html-scheme">Scheme 1</a>). The structures of the formed compounds were confirmed on the basis of elemental analyses and spectral data. Thus, the IR spectra of compounds <b>2</b>–<b>18</b> showed absorption bands for (NH), (CH aromatic), (CH aliphatic), (C=N) and (SO<sub>2</sub>) functional groups. The <sup>1</sup>H-NMR spectra exhibited singlets assigned to the NH group which were exchanged upon deuteration. Also, interaction of compound <b>1</b> with sulfanilamide in dimethylformamide in the presence of anhydrous K<sub>2</sub>CO<sub>3</sub> furnished 4-amino-<span class='html-italic'>N</span>-(2-phenylquinazoline-4-yl)-benzenesulfonamide (<b>19</b>, <a href="#molecules-21-00189-f004" class="html-scheme">Scheme 2</a>), this reaction proceeded through salt formation of the acidic amino group of sulfonamide (SO<sub>2</sub>NH<sub>2</sub>) which further reacted with the chloro group of the quinazoline to yield compound <b>19</b>. </div><div class="html-fig-wrap" id="molecules-21-00189-f003">
  <div class='html-fig_img'>
    <div class="html-figpopup html-figpopup-link" href="#fig_body_display_molecules-21-00189-f003">
      <img alt="Molecules 21 00189 g003 1024" data-large="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g003-1024.png" data-original="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g003.png" src="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g003-1024.png" />
      <a class="html-expand html-figpopup" href="#fig_body_display_molecules-21-00189-f003"></a>
    </div>

  </div>
  <div class="html-fig_description">
    <b>Scheme 1.</b>
      Synthetic pathways for compounds <b>2</b>–<b>18</b>.
<!--     <p><a class="html-figpopup" href="#fig_body_display_molecules-21-00189-f003">
      Click here to enlarge figure
    </a></p> -->

  </div>
</div>
<div class="html-fig_show  mfp-hide" id ="fig_body_display_molecules-21-00189-f003" >
  <div class="html-caption" > <b>Scheme 1.</b>
      Synthetic pathways for compounds <b>2</b>–<b>18</b>.</div>
  <div class="html-img"><img alt="Molecules 21 00189 g003 1024" data-large="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g003-1024.png" data-original="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g003.png" src="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g003-1024.png" /></div>
</div><div class="html-fig-wrap" id="molecules-21-00189-f004">
  <div class='html-fig_img'>
    <div class="html-figpopup html-figpopup-link" href="#fig_body_display_molecules-21-00189-f004">
      <img alt="Molecules 21 00189 g004 1024" data-large="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g004-1024.png" data-original="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g004.png" src="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g004-1024.png" />
      <a class="html-expand html-figpopup" href="#fig_body_display_molecules-21-00189-f004"></a>
    </div>

  </div>
  <div class="html-fig_description">
    <b>Scheme 2.</b>
      Synthetic pathways for compounds <b>19</b>–<b>21</b>.
<!--     <p><a class="html-figpopup" href="#fig_body_display_molecules-21-00189-f004">
      Click here to enlarge figure
    </a></p> -->

  </div>
</div>
<div class="html-fig_show  mfp-hide" id ="fig_body_display_molecules-21-00189-f004" >
  <div class="html-caption" > <b>Scheme 2.</b>
      Synthetic pathways for compounds <b>19</b>–<b>21</b>.</div>
  <div class="html-img"><img alt="Molecules 21 00189 g004 1024" data-large="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g004-1024.png" data-original="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g004.png" src="/molecules/molecules-21-00189/article_deploy/html/images/molecules-21-00189-g004-1024.png" /></div>
</div><div class='html-p'>The IR spectrum of compound <b>19</b> showed characteristic bands at 3412, 3209 cm<sup>−1</sup> (NH, NH<sub>2</sub>), 3084 cm<sup>−1</sup> (CH aromatic) 1635 cm<sup>−1</sup> (C=N), 1375, 1134 cm<sup>−1</sup> (SO<sub>2</sub>). The <sup>1</sup>H-NMR spectrum of compound <b>19</b> exhibited signals at 7.0 ppm due to the NH<sub>2</sub> group, which exchangeable with D<sub>2</sub>O, and a singlet at 11.9 ppm assigned to the NH group which was exchangeable with D<sub>2</sub>O. The mass spectrum of compound <b>19</b> revealed a molecular ion peak <span class='html-italic'>m</span>/<span class='html-italic'>z</span> at of 376[M<sup>+</sup>] (11.64). In addition, by interaction of compound <b>1</b> with dapsone in 1:1 molar ratio, <span class='html-italic'>N</span>-(4-(4-aminophenylsulfonyl)phenyl)-2-phenylquinazolin-4-amine (<b>20</b>) was formed, while, an additional mole of 2-phenylquinazolin-4-amine was introduced to give the bis-compound <b>21</b> under the same reaction conditions but using a 2:1 molar ratio. The structures of compounds <b>20</b> and <b>21</b> were confirmed on the basis of elemental analyses, IR, <sup>1</sup>H-NMR, <sup>13</sup>C-NMR and mass spectral data. The IR spectrum of compound <b>20</b> revealed characteristic bands at 3375, 3257, (NH, NH<sub>2</sub>), 1664 (C=O), 1618 (C=N), 1389, 1140 (SO<sub>2</sub>). The <sup>1</sup>H-NMR spectrum of compound <b>20</b> exhibited signals at 5.9 ppm due to a NH<sub>2</sub> group, which was exchangeable with D<sub>2</sub>O, and a singlet at 10.1 ppm assigned to a NH group which was exchangeable with D<sub>2</sub>O. The mass spectrum of compound <b>20</b> revealed a molecular ion peak at <span class='html-italic'>m</span>/<span class='html-italic'>z</span> 453 [M<sup>+</sup>] (13.72). The IR spectrum of <b>21</b> showed characteristic bands at 3367 (2NH), 1622 (2C=N), 1375, 1181 (SO<sub>2</sub>). The <sup>1</sup>H-NMR spectrum of <b>21</b> revealed signals at 10.1 ppm corresponding to two NH groups which were exchangeable with D<sub>2</sub>O. The mass spectrum of compound <b>21</b> showed a molecular ion peak at <span class='html-italic'>m</span>/<span class='html-italic'>z</span> 657 [M<sup>+</sup>] (32.18); this increase in the mass demonstrated the introduction of the second mole of dapsone.</div></section><section id='sec2dot2-molecules-21-00189' type=''><h4 class=html-italic data-nested='2'>  2.2. In-Vitro Anticancer Evaluation</h4><div class='html-p'>The synthesized compounds were evaluated for their <span class='html-italic'>in vitro</span> anticancer activity against human lung cancer cell line (A549), cervical (HeLa) cancer cell line, colorectal cell line (LoVo) and breast cancer cell line (MDA-MB-231) using doxorubicin as reference drug. The relationship between surviving fraction and drug concentration was plotted to obtain the survival curves of the cancer cell lines. The response parameter calculated was the IC<sub>50</sub> value, which corresponds to the concentration required for 50% inhibition of cell viability. The results are presented in <a href="#molecules-21-00189-t001" class="html-table">Table 1</a>, where all compounds exhibit moderate activity compared to doxorubicin as positive control. </div><div class="html-table-wrap" id="molecules-21-00189-t001">
  <div class="html-table_wrap_td" >
    <div class="html-tablepopup html-tablepopup-link" href='#table_body_display_molecules-21-00189-t001'>
        <img alt="Table" src="http://img.mdpi.org/img/table.png" />
       <a class="html-expand html-tablepopup" href="#table_body_display_molecules-21-00189-t001"></a>
    </div>

  </div>
  <div class="html-table_wrap_discription">
    <b>Table 1.</b>
    <span class='html-italic'>In vitro</span> anticancer screening of the synthesized compounds against four cell lines. Data are expressed as IC<sub>50</sub> (µM) ± SD (<span class='html-italic'>n</span> = 3).
  </div>
</div>
<div class="html-table_show  mfp-hide " id ="table_body_display_molecules-21-00189-t001" >
  
  <table >
    <caption ><b>Table 1.</b>
    <span class='html-italic'>In vitro</span> anticancer screening of the synthesized compounds against four cell lines. Data are expressed as IC<sub>50</sub> (µM) ± SD (<span class='html-italic'>n</span> = 3).</caption>
    <thead  ><tr  ><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >Cpd. No.</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >A549 (Lung Cancer Cells)</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >HeLa (Cervical)</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >LoVo (Colorectal Cancer Cells)</th><th align='center' valign='middle' style='border-top:solid thin;border-bottom:solid thin' >MDA-MB-231 (Breast Cancer Cells)</th></tr></thead><tbody  ><tr  ><td align='center' valign='middle' ><b>2</b></td><td align='center' valign='middle' >134.9 ± 0.40</td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >94.9 ± 0.78</td><td align='center' valign='middle' >58.2 ± 1.76</td></tr><tr  ><td align='center' valign='middle' ><b>3</b></td><td align='center' valign='middle' >113.5 ± 1.10</td><td align='center' valign='middle' >221.1 ± 1.22</td><td align='center' valign='middle' >80.5 ± 0.87</td><td align='center' valign='middle' >51.4 ± 1.32</td></tr><tr  ><td align='center' valign='middle' ><b>4</b></td><td align='center' valign='middle' >129.4 ± 0.71</td><td align='center' valign='middle' >187.7 ± 1.10</td><td align='center' valign='middle' >61.7 ± 1.31</td><td align='center' valign='middle' >36.4 ± 0.34</td></tr><tr  ><td align='center' valign='middle' ><b>5</b></td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >212.8 ± 0.78</td><td align='center' valign='middle' >NA</td></tr><tr  ><td align='center' valign='middle' ><b>6</b></td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >217.0 ± 1.11</td><td align='center' valign='middle' >NA</td></tr><tr  ><td align='center' valign='middle' ><b>7</b></td><td align='center' valign='middle' >77.8 ± 0.54</td><td align='center' valign='middle' >91.5 ± 0.41</td><td align='center' valign='middle' >96.5 ± 0.34</td><td align='center' valign='middle' >77.9 ± 0.36</td></tr><tr  ><td align='center' valign='middle' ><b>8</b></td><td align='center' valign='middle' >130.4 ± 0.67</td><td align='center' valign='middle' >284.6 ± 1.03</td><td align='center' valign='middle' >160.1 ± 0.90</td><td align='center' valign='middle' >97.4 ± 1.40</td></tr><tr  ><td align='center' valign='middle' ><b>9</b></td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >182.5 ± 0.33</td><td align='center' valign='middle' >NA</td></tr><tr  ><td align='center' valign='middle' ><b>10</b></td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >125.4 ± 0.88</td><td align='center' valign='middle' >154.1 ± 1.12</td></tr><tr  ><td align='center' valign='middle' ><b>11</b></td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >54.2 ± 0.92</td><td align='center' valign='middle' >NA</td></tr><tr  ><td align='center' valign='middle' ><b>12</b></td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >58.6 ±0.50</td><td align='center' valign='middle' >NA</td></tr><tr  ><td align='center' valign='middle' ><b>13</b></td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >112.9 ± 0.35</td><td align='center' valign='middle' >NA</td></tr><tr  ><td align='center' valign='middle' ><b>14</b></td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >101.7 ± 0.67</td><td align='center' valign='middle' >93.9 ± 0.45</td></tr><tr  ><td align='center' valign='middle' ><b>15</b></td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >61.5 ± 0.01</td><td align='center' valign='middle' >NA</td></tr><tr  ><td align='center' valign='middle' ><b>16</b></td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >65.5 ± 1.65</td><td align='center' valign='middle' >NA</td></tr><tr  ><td align='center' valign='middle' ><b>17</b></td><td align='center' valign='middle' >161.6 ± 0.78</td><td align='center' valign='middle' >87.6 ± 1.00</td><td align='center' valign='middle' >97.3 ± 0.23</td><td align='center' valign='middle' >42.8 ± 1.09</td></tr><tr  ><td align='center' valign='middle' ><b>18</b></td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >276.0 ± 1.01</td><td align='center' valign='middle' >132.0 ± 1.04</td><td align='center' valign='middle' >NA</td></tr><tr  ><td align='center' valign='middle' ><b>19</b></td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >146.4 ± 1.34</td><td align='center' valign='middle' >NA</td></tr><tr  ><td align='center' valign='middle' ><b>20</b></td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >251.6 ± 0.98</td><td align='center' valign='middle' >72.5 ± 0.26</td><td align='center' valign='middle' >NA</td></tr><tr  ><td align='center' valign='middle' ><b>21</b></td><td align='center' valign='middle' >NA</td><td align='center' valign='middle' >189.8 ± 1.12</td><td align='center' valign='middle' >73.1 ± 1.54</td><td align='center' valign='middle' >NA</td></tr><tr  ><td align='center' valign='middle' style='border-bottom:solid thin' >Doxorubicin</td><td align='center' valign='middle' style='border-bottom:solid thin' >283.5 ± 0.01</td><td align='center' valign='middle' style='border-bottom:solid thin' >120.7 ± 0.09</td><td align='center' valign='middle' style='border-bottom:solid thin' >374.4 ± 1.00</td><td align='center' valign='middle' style='border-bottom:solid thin' >26.5 ± 0.54</td></tr></tbody>
  </table>
  <div class='html-table_foot html-p'><div class='html-p' style='text-indent:0em;'><span class='html-fn-content'>NA = Not Active.</span></div></div>
</div><div class='html-p'>In the case of the human lung cancer cell line (A549) compounds <b>2</b>, <b>3</b>, <b>4</b>, <b>7</b>, <b>8</b>, and <b>17</b> were the most potent, with IC<sub>50</sub> values ranging from 77.8–161.6 µM, lower than the reference. On the other hand, the tested compounds showed low activity on the HeLa cell line where he most potent were the sulfonamide derivatives <b>7</b> and <b>17</b> (IC<sub>50</sub> = 91.5 and 87.6 µM, respectively). In case of the colorectal cell line LoVo, all compounds showed excellent activity and were found to be more active than doxorubicin. Moderate activity was observed for the synthesized compounds on the MDA-MB-231 breast cancer cell line, where the most potent candidates were compounds <b>2</b>–<b>4</b>, <b>7</b>, <b>8</b>, <b>10</b>, <b>14</b> and <b>17</b>, which all showed lower activity than the reference drug doxorubicin. Generally, the colorectal (LoVo) and breast (MDA-MB-231) cancer cell lines were the most sensitive to the synthesized compounds. With regard to broad spectrum anticancer activity, close examination of the data presented in <a href="#molecules-21-00189-t001" class="html-table">Table 1</a>, reveals that compounds <b>7</b> and <b>17</b> were the most active, showing effectiveness toward the four cell lines.</div></section></section><section id='sec3-molecules-21-00189' type=''><h2 data-nested='1'>  3. Materials and Methods</h2><section id='sec3dot1-molecules-21-00189' type=''><h4 class=html-italic data-nested='2'>  3.1. General Information</h4><div class='html-p'>All analyses were done at the Research Center, King Saud University (Riyadh, Saudi Arabia). Melting points (uncorrected) were determined in open capillaries on a Gallenkamp melting point apparatus (Sanyo Gallenkamp, Southborough, UK). Precoated silica gel plates (Kieselgel 0.25 mm, 60 F254, Merck, Darmstadt, Germany) were used for thin layer chromatography. A developing solvent system of 4:1 chloroform/methanol was used and the spots were detected by ultraviolet light. IR spectra (KBr discs) were recorded using an FT-IR spectrometer (Perkin Elmer, Waltham, MA, USA). <sup>1</sup>H-NMR spectra were scanned on NMR spectrometer (Bruker AXS Inc., Flawil, Switzerland), operating at 500 MHz for <sup>1</sup>H- and 125.76 MHz for <sup>13</sup>C. Chemical shifts are expressed in δ-values (ppm) relative to TMS as an internal standard, using DMSO-<span class='html-italic'>d</span><sub>6</sub> as a solvent. Mass spectra were recorded on a 600 GC/MS (Clarus, Middletown, CT, USA) and TQ 320 GC/MS/MS mass spectrometers (Varian, West Sussex, UK). Elemental analyses were done on a model 2400 CHNSO analyser (Perkin Elmer, Waltham, MA, USA). All the values were within ± 0.4% of the theoretical values. All reagents used were of AR grade. The starting material 4-chloro-2-phenylquinazoline was purchased from Sigma (St. Louis, MO, USA) and was directly used for the preparation of target compounds. Spectroscopic data of the synthesized compounds can be accessed as <a href="#app1-molecules-21-00189" class="html-app">supplementary materials</a>.</div></section><section id='sec3dot2-molecules-21-00189' type=''><h4 class=html-italic data-nested='2'>  3.2. General Procedure for the Synthesis of Sulfonamide Derivatives <b>2</b>–<b>18</b></h4><div class='html-p'>A mixture of 4-chloro-2-phenylquinazoline (<b>1</b>, 2.42 g, 0.01 mol) and sulfonamides (0.012 mol) in dry dimethylformamide (10 mL) was refluxed for 22 h., then left to cool. The solid product formed upon pouring onto ice/water was collected by filtration and recrystallized from ethanol-dimethylformamide to give <b>2</b>–<b>18</b>, respectively.</div><div class='html-p'><span class='html-italic'>4-(2-Phenylquinazolin-4-ylamino)benzenesulfonamide</span> (<b>2</b>). Yield, 89%; m.p. 209.3 °C. IR (KBr, cm<sup>−1</sup>): 3196, 3169, 3136 (NH, NH<sub>2</sub>), 3061 (CH arom.), 1670, 1602 (2C=N), 1394, 1190 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 7.4–8.5 (m, 15H, Ar-H + SO<sub>2</sub>NH<sub>2</sub>), 9.7 (s, 1H, NH exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 114.4 (2), 121.4, 125.6, 126.3 (2), 127.0, 127.9, 128.3 (2), 128.8 (2), 129.2, 130.4, 131.1, 133.0, 139.1, 149.2, 152.7, 160.2. MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 376 (M<sup>+</sup>) (23.42), 74 (100). Anal. Calcd. For C<sub>20</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>S (376): C, 63.81; H, 4. 28; N, 14.88. Found: C, 63.53; H, 4.50; N, 14.49.</div><div class='html-p'><span class='html-italic'>N</span><span class='html-italic'>-(4-(2-Phenylquinazolin-4-ylamino)phenylsulfonyl)acetamide</span> (<b>3</b>). Yield, 91%; m.p. 243.5 °C. IR (KBr, cm<sup>−1</sup>): 3412, 3269 (NH), 3100 (CH arom.), 2956, 2843 (CH aliph.), 1667 (C=O), 1602, 1571 (2C=N), 1344, 1189 (SO<sub>2</sub>). <sup>1</sup>H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 1.9 (s, 3H, COCH3), 7.3–8.7 (m, 14H, Ar-H + SO<sub>2</sub>NH), 12.5 (s, 1H, NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 23.6, 121.4 (2), 126.3, 126.8, 127.0 (2), 127.8 (2), 128.2 (2), 129.0, 129.1 (2), 131.8 (2), 133.1, 135.0, 149.0 (2), 152.8, 162.7. MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 418 (M<sup>+</sup>) (41.31), 122 (100). Anal. Calcd. For C<sub>22</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub>S (418): C, 63.14; H, 4. 34; N, 13.39. Found: C, 63.43; H, 4.10; N, 13.69.</div><div class='html-p'><span class='html-italic'>N</span><span class='html-italic'>-Carbamimidoyl-4-(2-phenylquinazolin-4-ylamino)benzenesulfonamide</span> (<b>4</b>). Yield, 78%; m.p. 314.4 °C. IR (KBr, cm<sup>−1</sup>): 3425, 3329, 3186 (NH, NH<sub>2</sub>), 3100 (CH arom.), 2928,2868 (CH aliph.), 1669, 1618, 1601 (C=N), 1397,1169 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 6.7 (s, 2H, NH<sub>2</sub>, exchangeable with D<sub>2</sub>O), 7.1, 8.4 (m, 14H, Ar-H + SO<sub>2</sub>NH), 8.6 (s, 1H, NH imino, exchangeable with D<sub>2</sub>O) ,10.1 (s, 1H,NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 114.4 (2), 121.4, 123.6, 126.3 (2), 127.0, 128.2, 128.4 (2), 129.0 (2), 131.0, 131.8, 133.1, 134.1, 139.5, 142.3, 158.2, 159.3, 162.7.MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 418 (M<sup>+</sup>) (25.4), 76 (100). Anal. Calcd. For C<sub>21</sub>H<sub>18</sub>N<sub>6</sub>O<sub>2</sub>S (418): C, 60.27; H, 4. 34; N, 20.08. Found: C, 60.55; H, 4.09; N, 20.31.</div><div class='html-p'><span class='html-italic'>N</span><span class='html-italic'>-(3-Methylisoxazol-5-yl)-4-(2-phenylquinazolin-4-ylamino)benzenesulfonamide</span> (<b>5</b>). Yield, 83%; m.p. 133.4 °C. IR (KBr, cm<sup>−1</sup>): 3323, 3196 (NH), 3061 (CH arom.), 2927, 2871 (CH aliph.), 1670, 1622, 1600 (C=N), 1357,1143 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 2.2 (s, 3H, CH<sub>3</sub>), 6.8 (s, 1H, CH isoxazole), 7.1–8.6 (m, 13H, Ar-H),10.2 (s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O),12.5 (s,1H,NH exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>):10.9, 98.3, 114.5 (2), 114.7, 123.5, 126.3 (2), 126.6, 127.0, 128.2 (2), 128.9, 130.5 (2), 131.8, 132.7, 135.0, 141.6, 149.2, 158.1, 159.3, 162.7, 163.2. MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 458 (M<sup>+</sup>) (24.54), 81 (100). Anal. Calcd. For C<sub>24</sub>H<sub>19</sub>N<sub>5</sub>O<sub>3</sub>S (458): C, 63.01; H, 4. 19; N, 15.31. Found: C, 63.29; H, 4.45; N, 15.61.</div><div class='html-p'><span class='html-italic'>N</span><span class='html-italic'>-(3,4-Dimethylisoxazol-5-yl)-4-(2-phenylquinazolin-4-yl-amino)benzenesulfonamide</span> (<b>6</b>). Yield, 77%; m.p. 114.0 °C. IR (KBr, cm<sup>−1</sup>): 3323, 3196 (NH), 3061 (CH arom.), 2927,2819 (CH aliph.), 1670, 1624 (C=N), 1373,1143 (SO<sub>2</sub>).<sup>1</sup> H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>):2.6, 2.7 (2s, 6H, 2CH<sub>3</sub>), 7.3, 8.6 (m, 13H, Ar-H), 10.1 (s, 1H,SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 12.5 (s, 1H, NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 6.8, 10.8, 101.8, 114.5 (2), 114.7, 124.7, 126.6 (2), 127.2, 128.2, 128.6(2), 128.9, 129.0 (2), 130.5, 131.5, 132.7, 143.0, 149.2, 158.1, 159.3, 162.7, 163.2.MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 472 (M<sup>+</sup>) (4.7), 65 (100). Anal.Calcd. For C<sub>25</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub>S (472): C, 63.68; H, 4. 49; N, 14.85. Found: C, 63.37; H, 4.27; N, 14.59.</div><div class='html-p'><span class='html-italic'>N</span><span class='html-italic'>-(1-Phenyl-1H-pyrazol-5-yl)-4-(2-phenylquinazolin-4-ylamino)benzenesulfonamide</span> (<b>7</b>). Yield, 89%; m.p. 232.6 °C. IR (KBr, cm<sup>−1</sup>): 3196, 3134 (NH), 3064 (CH arom.), 1670, 1602 (C=N), 1340, 1190 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 7.4–8.5 (m, 20H, Ar-H), 12.5 (s, 1H, SO<sub>2</sub>NH + NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 97.9, 115.2 (2), 121.4, 126.3 (2), 127.0 (2), 127.9, 128.2 (2), 128.3, 128.4, 128.7 (2), 128.9 (2), 129.0, 131.8 (2), 131.8, 133.2 (2), 135.0 (2), 149.2, 152.7, 162.7 (2). MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 519 (M<sup>+</sup>) (4.43), 103 (100). Anal.Calcd. For C<sub>29</sub>H<sub>22</sub>N<sub>6</sub>O<sub>2</sub>S (519): C, 67.17; H, 4. 28; N, 16.21. Found: C, 67.48; H, 4.52; N, 16.50.</div><div class='html-p'><span class='html-italic'>4</span><span class='html-italic'>-(2-Phenylquinazolin-4-ylamino)-N-(thiazol-2-yl)benzenesulfonamide</span> (<b>8</b>). Yield, 79%; m.p. 146.7 °C. IR (KBr, cm<sup>−1</sup>): 3487, 3381 (NH), 3084 (CH arom.), 1622, 1599 (C=N), 1358, 1178 (SO<sub>2</sub>). <sup>1</sup>H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 6.8–8.6 (m, 15H, Ar-H), 10.1 (s,1H,SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 12.7 (s, 1H,NH, exchangeable with D<sub>2</sub>O).<sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 108.5, 114.5 (2), 121.6, 124.9, 126.3 (2), 126.7, 127.0, 128.2 (2), 128.8, 130.9 (2), 131.8, 133.1, 133.9, 136.8, 143.2, 151.0, 158.1, 162.7, 169.1. MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 460 (M<sup>+</sup>) (9.59), 93 (100). Anal. Calcd. For C<sub>23</sub>H<sub>17</sub>N<sub>5</sub>O<sub>2</sub>S<sub>2</sub> (460): C, 60.11; H, 3.73; N, 15.24. Found: C, 60.43; H, 3.44; N, 15.50.</div><div class='html-p'><span class='html-italic'>N</span><span class='html-italic'>-(5-Methyl-1,3,4-thiadiazol-2-yl)-4-</span><span class='html-italic'>(2-phenylquinazolin-4-ylamino)benzenesulfonamide</span> (<b>9</b>). Yield, 80%; m.p. 188.9 °C. IR (KBr, cm<sup>−1</sup>): 3412, 3349 (NH), 3061 (CH arom.), 2923, 2859 (CH aliph.), 1622, 1600 (C=N), 1358,1184 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 2.4 (s, 3H<b>,</b> CH<sub>3</sub>), 7.3–8.6 (m, 13H, Ar-H), 10.1 (s,1H,SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 12.9 (s, 1H, NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 16.5, 114.5 (2), 114.6, 124.9 (2), 126.3, 126.7, 127.9, 128.4, 129.0 (2), 130.7 (2), 131.8, 133.0, 134.0, 138.5, 143.6, 149.2, 152.7, 158.1, 168.2. MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 474 (M<sup>+</sup>) (20.8), 163 (100). Anal. Calcd. For C<sub>23</sub>H<sub>18</sub>N<sub>6</sub>O<sub>2</sub>S<sub>2</sub> (474): C, 58.51; H, 3.82; N, 17.71. Found: C, 58.19; H, 3.58; N, 17.49.</div><div class='html-p'><span class='html-italic'>4-(2-Phenylquinazolin-4-ylamino)-N-(pyridine-2-yl)benzenesulfonamide</span> (<b>10</b>). Yield, 91%; m.p. 232.1 °C. IR (KBr, cm<sup>−1</sup>): 3365, 3209 (NH), 3067 (CH arom.), 1635, 1600 (C=N), 1355, 1134 (SO<sub>2</sub>). <sup>1</sup>H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 6.9–8.5 (m, 17H, Ar-H), 10.3 (s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 11.8 (s, 1H, NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 114.0, 114.5 (2), 116.4, 121.4, 123.5, 126.4 (2), 127.0, 127.9, 128.3 (2), 129.0, 130.8 (2), 131.8, 132.7, 133.3, 135.9, 140.5, 149.2, 151.0, 153.4, 159.3, 162.7. MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 454 (M<sup>+</sup>) (28.2), 79 (100). Anal.Calcd. For C<sub>25</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub>S (454): C, 66.21; H, 4. 22; N, 15.24. Found: C, 66.43; H, 4.52; N, 15.55.</div><div class='html-p'><span class='html-italic'>4-(2-Phenylquinazolin-4-ylamino)-N-(pyrimidin-2-yl)benzenesulfonamide</span> (<b>11</b>). Yield, 85%; m.p. 251.9 °C. IR (KBr, cm<sup>−1</sup>): 3167, 3129 (NH), 3084 (CH arom.), 1635 (C=O), 1683, 1600 (C=N), 1392, 1159 (SO<sub>2</sub>). <sup>1</sup>H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 6.9–8.5 (m, 16H, Ar-H), 10.1 (s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 12.5 (s, 1H, NH exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 114.5, 114.7 (2), 116.2, 124.7, 126.7 (2), 127.0, 128.2, 129.7 (2), 130.5, 130.9 (2), 131.8, 132.7, 133.1, 144.0, 149.2, 158.1 (2), 159.3, 162.7, 163.2. MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 455 (M<sup>+</sup>) (29.0), 158 (100). Anal. Calcd. For C<sub>24</sub>H<sub>18</sub>N<sub>6</sub>O<sub>2</sub>S (455): C, 63.42; H, 3.99; N, 18.49. Found: C, 63.14; H, 4.32; N, 18.12.</div><div class='html-p'><span class='html-italic'>N</span><span class='html-italic'>-(4-Methylpyrimidin-2-yl)-4-(2-phenylquinazolin-4-ylamino)benzenesulfonamide</span> (<b>12</b>). Yield, 78%; m.p. 261.1 °C. IR (KBr, cm<sup>−1</sup>): 3386, 3330 (NH), 3034 (CH arom.), 2962, 2870 (CH aliph.), 1624, 1599 (C=N), 1356,1147 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 2.3 (s, 3H, CH<sub>3</sub>), 6.9–8.5 (m, 15H, Ar-H), 10.1 (s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 11.7 (s, 1H,NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>):23.7, 112.5, 114.5 (2), 115.3, 124.7, 126.5 (2), 127.0, 128.2, 128.4 (2), 129.0, 130.5 (2), 131.8, 132.8, 133.1, 143.9, 149.2, 152.7, 157.1, 162.7, 163.1, 168.7. MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 469 (M<sup>+</sup>) (4.36), 171 (100). Anal. Calcd. For C<sub>25</sub>H<sub>20</sub>N<sub>6</sub>O<sub>2</sub>S (469): C, 64.09; H, 4.30; N, 17.94. Found: C, 64.30; H, 4.59; N, 17.68.</div><div class='html-p'><span class='html-italic'>N</span><span class='html-italic'>-(4,6-Dimethylpyrimidin-2-yl)-4-(2-phenylquinazolin-4-ylamino)benzenesulfonamide</span> (<b>13</b>). Yield, 90%; m.p. 232.8 °C. IR (KBr, cm<sup>−1</sup>): 3365, 3196 (NH), 3064 (CH arom.), 2954, 2861 (CH aliph.), 1670, 1618, 1597 (C=N), 1355,1155 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 2.3 (s, 6H, 2CH<sub>3</sub>), 6.7 (s, 1H CH pyrimidine), 7.1–8.6 (m, 13H, Ar-H), 10.0 (s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 12.5 (s,1H,NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 24.3 (2), 114.5, 114.7 (2), 121.0, 124.8, 126.7 (2), 127.0, 127.9, 128.3, 128.7 (2), 129.5 (2), 130.3, 131.8, 133.1, 138.3, 149.2, 151.0, 159.3 (2), 162.7, 163.2. MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 483 (M<sup>+</sup>) (28.71), 109 (100). Anal. Calcd. For C<sub>26</sub>H<sub>22</sub>N<sub>6</sub>O<sub>2</sub>S (483): C, 64.71; H, 4. 60; N, 17.42. Found: C, 64.45; H, 4.29; N, 17.70.</div><div class='html-p'><span class='html-italic'>N</span><span class='html-italic'>-(5-Methoxypyrimidin-2-yl)-4-(2-phenylquinazolin-4-ylamino)benzenesulfonamide</span> (<b>14</b>). Yield, 84%; m.p. 264.6 °C. IR (KBr, cm<sup>−1</sup>): 3423, 3221 (NH), 3100 (CH arom.), 2979, 2865 (CH aliph.), 1664, 1618, 1600 (C=N), 1356, 1161 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 3.7 (s, 3H, OCH<sub>3</sub>), 7.5–8.6 (m, 15H, Ar-H), 10.3 (s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 11.4 (s, 1H, NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 56.7, 112.6 (2), 114.5, 126.3, 126.7, 127.9 (2), 128.3, 128.7 (2), 128.8, 129.3 (2), 130.9, 131.8, 134.6, 138.0 (2), 143.9, 145.0, 149.2, 158.1, 159.3, 162.7. MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 485 (M<sup>+</sup>) (21.87), 74 (100). Anal. Calcd. For C<sub>25</sub>H<sub>20</sub>N<sub>6</sub>O<sub>3</sub>S (485): C, 61.97; H, 4.16; N, 17.34. Found: C, 61.66; H, 4.33; N, 17.60.</div><div class='html-p'><span class='html-italic'>N</span><span class='html-italic'>-(2,6-Dimethoxypyrimidin-4-yl)-4-(2-phenylquinazolin-4-ylamino)benzenesulfonamide</span> (<b>15</b>). Yield, 87%; m.p. 367.8 °C. IR (KBr, cm<sup>−1</sup>): 3221, 3169 (NH), 3057 (CH arom.), 2980, 2850 (CH aliph.), 1670, 1618, 1602 (C=N), 1388,1147 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 3.72, 3.79 (2s, 6H, 2OCH<sub>3</sub>), 6.1 (s, 1H, CH pyrimidine), 7.3–8.8 (m, 13H, Ar-H), 10.0 (s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 11.4 (s, 1H,NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 55.6 (2), 84.3, 114.4 (2), 121.4, 123.6, 126.7 (2), 127.0, 127.9, 128.4 (2), 129.9, 130.9 (2), 131.8, 133.1, 135.0, 142.9, 149.1, 156.0, 159.3, 161.7, 162.6, 162.7. MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 515 (M<sup>+</sup>) (5.19), 154 (100). Anal. Calcd. For C<sub>26</sub>H<sub>22</sub>N<sub>6</sub>O<sub>4</sub>S (515): C, 60.69; H, 4.31; N, 16.33. Found: C, 60.40; H, 4.62; N, 16.03.</div><div class='html-p'><span class='html-italic'>N</span><span class='html-italic'>-(5,6-Dimethoxypyrimidin-4-yl)-4-(2-phenylquinazolin-4-yl-amino)benzenesulfonamide</span> (<b>16</b>). Yield, 79%; m.p. 139.0 °C. IR (KBr, cm<sup>−1</sup>): 3360, 3192 (NH), 3059 (CH arom.), 2941, 2863 (CH aliph.), 1670, 1602 (C=N), 1328, 1188 (SO<sub>2</sub>). <sup>1</sup>H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 3.73, 3.74 (2s, 6H, 2OCH<sub>3</sub>), 7.2–8.2 (m, 14H, Ar-H), 8.5 (s, 1H, CH pyrimidine), 10.1 (s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 12.5 (s, 1H,NH, exchangeable with D<sub>2</sub>O).<sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 59.4 (2), 114.5 (2), 114.6, 125.0, 126.5 (2), 127.9, 128.2, 128.4 (2), 129.0, 130.2 (2), 130.6, 131.8, 133.1, 134.0, 143.9, 147.2, 152.7, 158.2, 159.3, 162.7, 162.8. MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 515 (M<sup>+</sup>) (28.12), 168 (100). Anal. Calcd. For C<sub>26</sub>H<sub>22</sub>N<sub>6</sub>O<sub>4</sub>S (515): C, 60.69; H, 4.31; N, 16.33. Found: C, 60.44; H, 4.04; N, 16.09.</div><div class='html-p'><span class='html-italic'>N</span><span class='html-italic'>-(1H-Indazol-6-yl)-4-(2-phenylquinazolin-4-ylamino)benzenesulfonamide</span> (<b>17</b>). Yield, 89%; m.p. 149.9 °C. IR (KBr, cm<sup>−1</sup>): 3192, 3134 (NH), 3062 (CH arom.), 1635, 1624, 1600 (C=N), 1375, 1149 (SO<sub>2</sub>). <sup>1</sup>H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 6.9–8.4 (m, 17H, Ar-H), 8.5, 10.1 (2s, 2H, SO<sub>2</sub>NH + NH, exchangeable with D<sub>2</sub>O), 12.9 (s, 1H, NH pyrazole, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 100.5, 114.5, 114.8, 115.4 (2), 120.2, 121.3, 124.7, 126.3 (2), 127.0, 127.9, 128.2 (2), 128.6, 130.5 (2), 130.8, 131.8, 132.7, 133.2, 140.8, 144.0, 151.0, 158.3, 162.7. MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 493 (M<sup>+</sup>) (30.31), 117 (100). Anal. Calcd. For C<sub>27</sub>H<sub>20</sub>N<sub>6</sub>O<sub>2</sub>S (493): C, 65.84; H, 4.09; N, 17.06. Found: C, 65.46; H, 4.30; N, 17.29.</div><div class='html-p'><span class='html-italic'>4-(2-Phenylquinazolin-4-ylamino)-N-(quinoxalin2-yl)benzenesulfonamide</span> (<b>18</b>). Yield, 76%; m.p. 154.8 °C. IR (KBr, cm<sup>−1</sup>): 3194, 3134 (NH), 3059 (CH arom.), 1670, 1600 (C=N), 1338, 1161 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 7.4–8.6 (m, 18H, Ar-H), 10.1 (s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O), 12.5 (s, 1H, NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 114.5 (2), 114.6, 121.4, 123.5, 124.9, 126.3 (2), 126.5, 127.0, 127.7, 127.9, 128.2 (2), 128.7, 129.0, 129.2, 130.6, 130.9, 133.1, 134.0, 135.0, 138.4, 144.3, 146.6, 152.7, 162.7, 163.2. MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 505 (M<sup>+</sup>) (26.73), 175 (100). Anal.Calcd. For C<sub>28</sub>H<sub>20</sub>N<sub>6</sub>O<sub>2</sub>S (505): C, 66.65; H, 4.00; N, 16.66. Found: C, 66.93; H, 4.31; N, 16.34.</div><div class='html-p'><span class='html-italic'>4-Amino-N-(2-phenylquinazolin-4-yl)benzenesulfonamide</span> (<b>19</b>). A mixture of compound 1 (2.42 g, 0.01 mol), sulfanilamide (1.72 g, 0.01 mol) and anhydrous potassium carbonate (1.38 g, 0.01 mol) in dry dimethylformamide (15 mL) was refluxed for 18 h. The obtained solid was recrystallized from dioxane to give 19. Yield, 68%; m.p. 245.9 °C. IR (KBr, cm<sup>−1</sup>): 3394, 3209 (NH, NH<sub>2</sub>), 3059 (CH arom.), 1635, 1608 (C=N), 1375, 1134 (SO<sub>2</sub>). <sup>1</sup>H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 7.0 (s, 2H, NH<sub>2</sub>, exchangeable with D<sub>2</sub>O), 7.5–9.0 (m, 13H, Ar-H], 11.9 [s, 1H, SO<sub>2</sub>NH, exchangeable with D<sub>2</sub>O]. <sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 113.2 (2), 116.6, 124.4, 126.3 (2), 127.7, 127.8, 128.7 (2), 129.2, 129.8 (2), 131.7, 132.4, 132.8, 141.6, 157.7, 159.9, 162.7. MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 376 (M<sup>+</sup>) (22.25), 155 (100). Anal.Calcd. For C<sub>20</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>S (376): C, 63.81; H, 4.28; N, 14.88. Found: C, 63.54; H, 4.01; N, 14.56.</div><div class='html-p'><span class='html-italic'>N</span><span class='html-italic'>-(4-(4-Aminophenylsulfonyl)phenyl)-2-phenylquinazolin-4-amine</span> (<b>20</b>). A mixture of 1 (2.42 g, 0.01 mol) and dapsone (2.48 g, 0.01 mol) in dry dimethylformamide (10 mL) was refluxed for 12 h. The obtained solid while hot was recrystallized from dioxane to give 20. Yield, 77%; m.p. 116.8 °C. IR (KBr, cm<sup>−1</sup>): 3415, 3375(NH, NH<sub>2</sub>), 3059 (CH arom.), 1618, 1595 (C=N), 1369, 1140 (SO<sub>2</sub>).<sup>1</sup>H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 5.9 (s, 2H, NH<sub>2</sub>, exchangeable with D<sub>2</sub>O), 6.5–8.6 (m, 17H, Ar-H), 10.1 (s, 1H, NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 113.3 (2), 114.4 (2), 114.5, 122.9, 125.7 (2), 126.3, 127.0, 128.1 (2), 129.2 (4), 129.7, 130.2 (2), 131.8, 133.0, 143.8, 149.2, 152.7, 159.7, 162.7. MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 453 (M<sup>+</sup>) (32.53), 92 (100). Anal. Calcd. For C<sub>26</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>S (453): C, 69.01; H, 4.45; N, 12.28. Found: C, 69.32; H, 4.71; N, 12.49.</div><div class='html-p'><span class='html-italic'>N</span><span class='html-italic'>,N′-(4,4′-Sulfonylbis(4,1-phenylene)bis(2-phenylquinazolin-4-amine)</span> (<b>21</b>). A mixture of 1 (4.84 g, 0.02 mol) and dapsone (2.48 g, 0.01 mol) in dry dimethylformamide (10 mL) was refluxed for 18 h. The obtained solid while hot was recrystallized from acetic acid to give 21. Yield, 68%; m.p. 197.9 °C. IR (KBr, cm<sup>−1</sup>): 3367, 3195 (NH), 3060 (CH arom.), 1622, 1597 (C=N), 1385, 1181 (SO<sub>2</sub>). <sup>1</sup>H-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 7.4–8.6 (m, 26H, Ar-H), 10.1 (s, 2H, 2NH, exchangeable with D<sub>2</sub>O). <sup>13</sup>C-NMR (DMSO-<span class='html-italic'>d</span><sub>6</sub>): 113.4 (4), 114.5 (2), 126.3 (2), 126.8 (2), 127.9 (4), 128.2 (2), 128.6 (4), 129.7 (4), 131.8 (2), 133.1 (2), 134.0(2), 135.0 (2), 143.8 (2), 149.2 (2), 153.9 (2), 158.1 (2). MS <span class='html-italic'>m</span>/<span class='html-italic'>z</span> (%): 657 (M<sup>+</sup>) (9.30), 271(100). Anal. Calcd. For C<sub>40</sub>H<sub>28</sub>N<sub>6</sub>O<sub>2</sub>S (657): C, 73.15; H, 4.30; N, 12.80. Found: C, 73.37; H, 4.66; N, 13.09.</div></section><section id='sec3dot3-molecules-21-00189' type=''><h4 class=html-italic data-nested='2'>  3.3. In-Vitro Anticancer Evaluation</h4><section id='sec3dot3dot1-molecules-21-00189' type=''><h4 class= data-nested='3'>  3.3.1. Cell Culture</h4><div class='html-p'>Human cancer cell lines HeLa (cervical), A549 (lungs) and LoVo (colorectal) were grown in DMEM + GlutaMax (Invitrogen, Carlsbad, CA, USA), and MDA-MB-231 (breast) were grown in DMEM-F12 + GlutaMax) medium (Invitrogen), supplemented with 10% heat-inactivated bovine serum (Gibco) and penicillin-streptomycin (Gibco, Gaithersburg, MD, USA) at 37 °C in a humified chamber with 5% CO<sub>2</sub> supply.</div></section><section id='sec3dot3dot2-molecules-21-00189' type=''><h4 class= data-nested='3'>  3.3.2. Cytotoxicity Assay</h4><div class='html-p'>The <span class='html-italic'>in vitro</span> anticancer screening was done at Pharmacognosy Department, College of Pharmacy, King Saud University (Riyadh, Saudi Arabia). Cells were seeded (10<sup>5</sup> cells/well) in 96-well flat-bottom plates (Becton-Dickinson Labware, Franklin Lakes, NJ, USA) a day before treatment and grown overnight. Compounds were dissolved in dimethyl sulfoxide (DMSO; Sigma) and finally prepared as 1.0 mg/mL stocks, respectively in the culture media. The final concentration of DMSO never exceeded 0.1% in the treatment doses. Six different doses of compounds (400, 200, 100, 50, 25 and 10 µM) were further prepared by diluting the stocks in culture media, and cells were treated (in triplicate/dose). Doxorubicin was included as standard reference drug (positive control) and untreated culture was considered as negative control. The cultures were further incubated for 48 hrs. At 48 h post-treatment, cell viability test was performed using TACS MTT Cell Proliferation and Viability Assay Kit (TACS) as per manufacturer’s instructions. The optical density (OD) was recorded at 570 nm in a microplate reader (ELx800, BioTek, Winooski, VT, USA) and cell survival fraction was determined. The cell survival fraction was calculated as [(A − B)/A], where A and B are the OD of untreated and of treated cells, respectively. The relation between surviving fraction and drug concentration is plotted to get the survival curve of each tumor cell line after the specified time. The concentration required for 50% inhibition of cell viability (IC<sub>50</sub>) was calculated and compared with the reference drug doxorubicin and the results are given in <a href="#molecules-21-00189-t001" class="html-table">Table 1</a>. Surviving curves for doxorubicin can be accessed as <a href="#app1-molecules-21-00189" class="html-app">supplementary materials</a>.</div></section></section></section><section id='sec4-molecules-21-00189' type='conclusions'><h2 data-nested='1'>  4. Conclusions</h2><div class='html-p'>In this work, novel quinazoline-sulfonamide hybrids were synthesized and their <span class='html-italic'>in vitro</span> anticancer activity was evaluated on four human cancer cell lines, among the tested compounds, two candidates (compounds <b>7</b> and <b>17</b>) showed effectiveness on the four cell lines, the active compounds could be considered as useful templates for further development to obtain more potent anticancer agent(s).</div></section>
  </div>
  <div class="html-back">
    <section><section id='app1-molecules-21-00189' type=''><h2 data-nested='1'>  Supplementary Materials</h2><div class='html-p'>Supplementary materials can be accessed at: <a href='http://www.mdpi.com/1420-3049/21/2/189/s1' target='_blank'>http://www.mdpi.com/1420-3049/21/2/189/s1</a>.</div></section></section><section id='html-ack' class='html-ack'><h2 >Acknowledgments</h2><div class='html-p'>The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for its funding of this research through the Research Group Project No. RGP-VPP-302.</div></section><section id='html-notes' class='html-notes'><h2 >Author Contributions</h2><div class='html-p'>M.M.G. suggested the research idea, contributed in the experimental work and in writing the paper. M.S.A. contributed in the experimental work, the biological activity and in writing the paper. M.S.A.-D., M.K.P. contributed in the biological activity. M.G.E.-G. contributed in the experimental work.</div></section><section id='html-notes' class='html-notes'><h2 >Conflicts of Interest</h2><div class='html-p'>The authors declare no conflict of interest.</div></section><section id='html-references_list'><h2>References</h2><ol class='html-xx'><li id='B1-molecules-21-00189' class='html-x' data-content='1.'>Medina, J.C.; Roche, D.; Shan, B.; Learned, R.M.; Frankmoelle, W.P.; Clark, D.L.; Rosen, T.; Jaen, J.C. Novel halogenated sulfonamides inhibit the growth of multidrug resistant MCF-7/ADR cancer cells. <span class='html-italic'>Bioorg. Med. Chem. Lett.</span> <b>1999</b>, <span class='html-italic'>9</span>, 1843–1846. [<a href="http://scholar.google.com/scholar_lookup?title=Novel halogenated sulfonamides inhibit the growth of multidrug resistant MCF-7/ADR cancer cells&author=Medina,+J.C.&author=Roche,+D.&author=Shan,+B.&author=Learned,+R.M.&author=Frankmoelle,+W.P.&author=Clark,+D.L.&author=Rosen,+T.&author=Jaen,+J.C.&publication_year=1999&journal=Bioorg.+Med.+Chem.+Lett.&volume=9&pages=1843–1846&pmid=10406652" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/10406652" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B2-molecules-21-00189' class='html-x' data-content='2.'>Hwang, H.S.; Moon, E.Y.; Seong, S.K.; Choi, C.H.; Chung, C.H.; Jung, S.H.; Yoon, S.J. Characterization of the anticancer activity of DW2282, a new anticancer agent. <span class='html-italic'>Anticancer Res.</span> <b>1999</b>, <span class='html-italic'>19</span>, 5087–5093. [<a href="http://scholar.google.com/scholar_lookup?title=Characterization of the anticancer activity of DW2282, a new anticancer agent&author=Hwang,+H.S.&author=Moon,+E.Y.&author=Seong,+S.K.&author=Choi,+C.H.&author=Chung,+C.H.&author=Jung,+S.H.&author=Yoon,+S.J.&publication_year=1999&journal=Anticancer+Res.&volume=19&pages=5087–5093&pmid=10697515" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/10697515" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B3-molecules-21-00189' class='html-x' data-content='3.'>Choo, H.Y.P.; Kim, M.; Lee, S.K.; Kim, S.W.; Chung, S.W. Solid-phase combinatorial synthesis and cytotoxicity of 3-aryl-2,4-quinazolindiones. <span class='html-italic'>Bioorg. Med. Chem.</span> <b>2002</b>, <span class='html-italic'>10</span>, 517–23. [<a href="http://scholar.google.com/scholar_lookup?title=Solid-phase combinatorial synthesis and cytotoxicity of 3-aryl-2,4-quinazolindiones&author=Choo,+H.Y.P.&author=Kim,+M.&author=Lee,+S.K.&author=Kim,+S.W.&author=Chung,+S.W.&publication_year=2002&journal=Bioorg.+Med.+Chem.&volume=10&pages=517–23&pmid=11814837" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/11814837" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B4-molecules-21-00189' class='html-x' data-content='4.'>Antonello, A.; Tarozzi, A.; Morroni, F.; Cavalli, A.; Rosini, M.; Hrelia, P.; Bolognesi, M.L.; Melchiorre, C. Multitarget-directed drug design strategy: A novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects. <span class='html-italic'>J. Med. Chem.</span> <b>2006</b>, <span class='html-italic'>49</span>, 6642–6645. [<a href="http://scholar.google.com/scholar_lookup?title=Multitarget-directed drug design strategy: A novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects&author=Antonello,+A.&author=Tarozzi,+A.&author=Morroni,+F.&author=Cavalli,+A.&author=Rosini,+M.&author=Hrelia,+P.&author=Bolognesi,+M.L.&author=Melchiorre,+C.&publication_year=2006&journal=J.+Med.+Chem.&volume=49&pages=6642–6645&pmid=17154492" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/17154492" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B5-molecules-21-00189' class='html-x' data-content='5.'>Rachid, Z.; Brahimi, F.; Qiu, Q.; Williams, C.; Hartley, J.M.; Hartley, J.A.; Jean-Claude, B.J. Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: Discovery of an unusual structure activity relationship. <span class='html-italic'>J. Med. Chem.</span> <b>2007</b>, <span class='html-italic'>50</span>, 2605–2608. [<a href="http://scholar.google.com/scholar_lookup?title=Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: Discovery of an unusual structure activity relationship&author=Rachid,+Z.&author=Brahimi,+F.&author=Qiu,+Q.&author=Williams,+C.&author=Hartley,+J.M.&author=Hartley,+J.A.&author=Jean-Claude,+B.J.&publication_year=2007&journal=J.+Med.+Chem.&volume=50&pages=2605–2608&pmid=17472358" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/17472358" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B6-molecules-21-00189' class='html-x' data-content='6.'>Baselga, J.; Swain, S.M. Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. <span class='html-italic'>Nat. Rev. Cancer</span> <b>2009</b>, <span class='html-italic'>9</span>, 463–475. [<a href="http://scholar.google.com/scholar_lookup?title=Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3&author=Baselga,+J.&author=Swain,+S.M.&publication_year=2009&journal=Nat.+Rev.+Cancer&volume=9&pages=463–475&doi=10.1038/nrc2656&pmid=19536107" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1038/nrc2656" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/19536107" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B7-molecules-21-00189' class='html-x' data-content='7.'>Brown, C.H.J.; Lain, S.; Verma, C.H.S.; Fersht, A.R.; Lane, D.P. Awakening guardian angels: Drugging the p53 pathway. <span class='html-italic'>Nat. Rev. Cancer</span> <b>2009</b>, <span class='html-italic'>9</span>, 862–873. [<a href="http://scholar.google.com/scholar_lookup?title=Awakening guardian angels: Drugging the p53 pathway&author=Brown,+C.H.J.&author=Lain,+S.&author=Verma,+C.H.S.&author=Fersht,+A.R.&author=Lane,+D.P.&publication_year=2009&journal=Nat.+Rev.+Cancer&volume=9&pages=862–873&pmid=19935675" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/19935675" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B8-molecules-21-00189' class='html-x' data-content='8.'>Li, X.; Lu, X.; Xing, M.; Yang, X.H.; Zhao, T.T.; Gong, H.B.; Zhu, H.L. Synthesis, biological evaluation, and molecular docking studies of <span class='html-italic'>N</span>,1,3-triphenyl-1<span class='html-italic'>H</span>-pyrazole-4 carboxamide derivatives as anticancer agents. <span class='html-italic'>Bioorg. Med. Chem. Lett.</span> <b>2012</b>, <span class='html-italic'>22</span>, 3589–3593. [<a href="http://scholar.google.com/scholar_lookup?title=Synthesis, biological evaluation, and molecular docking studies of N,1,3-triphenyl-1H-pyrazole-4 carboxamide derivatives as anticancer agents&author=Li,+X.&author=Lu,+X.&author=Xing,+M.&author=Yang,+X.H.&author=Zhao,+T.T.&author=Gong,+H.B.&author=Zhu,+H.L.&publication_year=2012&journal=Bioorg.+Med.+Chem.+Lett.&volume=22&pages=3589–3593&pmid=22572580" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/22572580" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B9-molecules-21-00189' class='html-x' data-content='9.'>Kidwai, M.; Venkataramanan, R.; Mohan, R.; Sapra, P. Chemotherapy and heterocyclic compounds. <span class='html-italic'>Curr. Med. Chem.</span> <b>2002</b>, <span class='html-italic'>9</span>, 1209–1228. [<a href="http://scholar.google.com/scholar_lookup?title=Chemotherapy and heterocyclic compounds&author=Kidwai,+M.&author=Venkataramanan,+R.&author=Mohan,+R.&author=Sapra,+P.&publication_year=2002&journal=Curr.+Med.+Chem.&volume=9&pages=1209–1228&pmid=12052173" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/12052173" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B10-molecules-21-00189' class='html-xx' data-content='10.'>Salimon, J.; Salih, N.; Yousif, E.; Hameed, A.; Ibraheem, H. Synthesis and antibacterial activity of some new 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives. <span class='html-italic'>Aust. J. Basic Appl. Sci.</span> <b>2010</b>, <span class='html-italic'>4</span>, 2016–2021. [<a href="http://scholar.google.com/scholar_lookup?title=Synthesis and antibacterial activity of some new 1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives&author=Salimon,+J.&author=Salih,+N.&author=Yousif,+E.&author=Hameed,+A.&author=Ibraheem,+H.&publication_year=2010&journal=Aust.+J.+Basic+Appl.+Sci.&volume=4&pages=2016–2021" class='google-scholar' target='_blank'>Google Scholar</a>]</li><li id='B11-molecules-21-00189' class='html-xx' data-content='11.'>Mohamed, H.A.; Lake, B.R.; Laing, T.; Phillips, R.M.; Willans, C.E. Synthesis and anticancer activity of silver(I)-<span class='html-italic'>N</span>-heterocyclic carbene complexes derived from the natural xanthine products caffeine, theophylline and theobromine. <span class='html-italic'>Dalton Trans.</span> <b>2015</b>, <span class='html-italic'>44</span>, 7563–7569. [<a href="http://scholar.google.com/scholar_lookup?title=Synthesis and anticancer activity of silver(I)-N-heterocyclic carbene complexes derived from the natural xanthine products caffeine, theophylline and theobromine&author=Mohamed,+H.A.&author=Lake,+B.R.&author=Laing,+T.&author=Phillips,+R.M.&author=Willans,+C.E.&publication_year=2015&journal=Dalton+Trans.&volume=44&pages=7563–7569&pmid=25812062" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/25812062" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B12-molecules-21-00189' class='html-xx' data-content='12.'>Srivastava, S.K.; Kumar, V.; Agarwal, S.K.; Mukherjee, R.; Burman, A.C. Synthesis of quinazolines as tyrosine kinase inhibitors. <span class='html-italic'>Anticancer Agents Med. Chem.</span> <b>2009</b>, <span class='html-italic'>9</span>, 246–275. [<a href="http://scholar.google.com/scholar_lookup?title=Synthesis of quinazolines as tyrosine kinase inhibitors&author=Srivastava,+S.K.&author=Kumar,+V.&author=Agarwal,+S.K.&author=Mukherjee,+R.&author=Burman,+A.C.&publication_year=2009&journal=Anticancer+Agents+Med.+Chem.&volume=9&pages=246–275&doi=10.2174/1871520610909030246&pmid=19275520" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.2174/1871520610909030246" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/19275520" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B13-molecules-21-00189' class='html-xx' data-content='13.'>Cruz-López, O.; Conejo-García, A.; Núñez, M.C.; Kimatrai, M.; García-Rubiño, M.E.; Morales, F.; Gómez-Pérez, V.; Campos, J.M. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors. <span class='html-italic'>Curr. Med. Chem.</span> <b>2011</b>, <span class='html-italic'>18</span>, 943–963. [<a href="http://scholar.google.com/scholar_lookup?title=Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors&author=Cruz-López,+O.&author=Conejo-García,+A.&author=Núñez,+M.C.&author=Kimatrai,+M.&author=García-Rubiño,+M.E.&author=Morales,+F.&author=Gómez-Pérez,+V.&author=Campos,+J.M.&publication_year=2011&journal=Curr.+Med.+Chem.&volume=18&pages=943–963&pmid=21254978" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/21254978" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B14-molecules-21-00189' class='html-xx' data-content='14.'>Garofalo, A.; Goossens, L.; Six, P.; Lemoine, A.; Ravez, S.; Farce, A.; Depreux, P. Impact of aryloxy-linked quinazolines: A novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors. <span class='html-italic'>Bioorg. Med. Chem. Lett.</span> <b>2011</b>, <span class='html-italic'>21</span>, 2106–2112. [<a href="http://scholar.google.com/scholar_lookup?title=Impact of aryloxy-linked quinazolines: A novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors&author=Garofalo,+A.&author=Goossens,+L.&author=Six,+P.&author=Lemoine,+A.&author=Ravez,+S.&author=Farce,+A.&author=Depreux,+P.&publication_year=2011&journal=Bioorg.+Med.+Chem.+Lett.&volume=21&pages=2106–2112&pmid=21353546" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/21353546" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B15-molecules-21-00189' class='html-xx' data-content='15.'>Lüth, B.; Löwe, W. Syntheses of 4-(indole-3-yl)quinazolines: A new class of epidermal growth factor receptor tyrosine kinase inhibitors. <span class='html-italic'>Eur. J. Med. Chem.</span> <b>2008</b>, <span class='html-italic'>43</span>, 1478–1488. [<a href="http://scholar.google.com/scholar_lookup?title=Syntheses of 4-(indole-3-yl)quinazolines: A new class of epidermal growth factor receptor tyrosine kinase inhibitors&author=Lüth,+B.&author=Löwe,+W.&publication_year=2008&journal=Eur.+J.+Med.+Chem.&volume=43&pages=1478–1488&pmid=17981366" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/17981366" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B16-molecules-21-00189' class='html-xx' data-content='16.'>Lee, Y.S.; Seo, S.H.; Yang, B.S.; Lee, J.Y. Synthesis and biological evaluation of bis(methoxy methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolines as EGFR tyrosine kinase inhibitors. <span class='html-italic'>Arch. Pharm.</span> <b>2005</b>, <span class='html-italic'>338</span>, 502–505. [<a href="http://scholar.google.com/scholar_lookup?title=Synthesis and biological evaluation of bis(methoxy methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolines as EGFR tyrosine kinase inhibitors&author=Lee,+Y.S.&author=Seo,+S.H.&author=Yang,+B.S.&author=Lee,+J.Y.&publication_year=2005&journal=Arch.+Pharm.&volume=338&pages=502–505" class='google-scholar' target='_blank'>Google Scholar</a>]</li><li id='B17-molecules-21-00189' class='html-xx' data-content='17.'>Cui, G.; Cui, M.; Li, Y.; Liang, Y.; Li, W.; Guo, H.; Zha, S. Galectin-3 knockdown increases gefitinib sensitivity to the inhibition of EGFR endocytosis in gefitinib insensitive esophageal squamous cancer cells. <span class='html-italic'>Med. Oncol.</span> <b>2015</b>, <span class='html-italic'>32</span>, 570–76. [<a href="http://scholar.google.com/scholar_lookup?title=Galectin-3 knockdown increases gefitinib sensitivity to the inhibition of EGFR endocytosis in gefitinib insensitive esophageal squamous cancer cells&author=Cui,+G.&author=Cui,+M.&author=Li,+Y.&author=Liang,+Y.&author=Li,+W.&author=Guo,+H.&author=Zha,+S.&publication_year=2015&journal=Med.+Oncol.&volume=32&pages=570–76" class='google-scholar' target='_blank'>Google Scholar</a>]</li><li id='B18-molecules-21-00189' class='html-xx' data-content='18.'>Mathew, M.P.; Tan, E.; Saeui, C.T.; Bovonratwet, P.; Liu, L.; Bhattacharya, R.; Yarema, K.J. Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib. <span class='html-italic'>Bioorg. Med. Chem. Lett.</span> <b>2015</b>, <span class='html-italic'>25</span>, 1223–1227. [<a href="http://scholar.google.com/scholar_lookup?title=Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib&author=Mathew,+M.P.&author=Tan,+E.&author=Saeui,+C.T.&author=Bovonratwet,+P.&author=Liu,+L.&author=Bhattacharya,+R.&author=Yarema,+K.J.&publication_year=2015&journal=Bioorg.+Med.+Chem.+Lett.&volume=25&pages=1223–1227&doi=10.1016/j.bmcl.2015.01.060&pmid=25690786" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1016/j.bmcl.2015.01.060" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/25690786" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B19-molecules-21-00189' class='html-xx' data-content='19.'>Bellizzi, A.; Greco, M.R.; Rubino, R.; Paradiso, A.; Forciniti, S.; Zeeberg, K.; Cardone, R.A.; Reshkin, S.J. The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells. <span class='html-italic'>Int. J. Oncol.</span> <b>2015</b>, <span class='html-italic'>46</span>, 1214–1224. [<a href="http://scholar.google.com/scholar_lookup?title=The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells&author=Bellizzi,+A.&author=Greco,+M.R.&author=Rubino,+R.&author=Paradiso,+A.&author=Forciniti,+S.&author=Zeeberg,+K.&author=Cardone,+R.A.&author=Reshkin,+S.J.&publication_year=2015&journal=Int.+J.+Oncol.&volume=46&pages=1214–1224&pmid=25530180" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/25530180" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B20-molecules-21-00189' class='html-xx' data-content='20.'>Jackman, D.M.; Cioffredi, L.A.; Sharmeen, L.; Morse, L.K.; Lucca, J.; Plotkin, S.R.; Marcoux, P.J.; Rabin, M.S.; Lynch, T.J.; Johnson, B.E.; <span class='html-italic'>et al</span>. A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. <span class='html-italic'>Oncotarget</span> <b>2015</b>, <span class='html-italic'>6</span>, 4527–4536. [<a href="http://scholar.google.com/scholar_lookup?title=A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer&author=Jackman,+D.M.&author=Cioffredi,+L.A.&author=Sharmeen,+L.&author=Morse,+L.K.&author=Lucca,+J.&author=Plotkin,+S.R.&author=Marcoux,+P.J.&author=Rabin,+M.S.&author=Lynch,+T.J.&author=Johnson,+B.E.&publication_year=2015&journal=Oncotarget&volume=6&pages=4527–4536&pmid=25784657" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/25784657" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B21-molecules-21-00189' class='html-xx' data-content='21.'>Nakao, M.; Muramatsu, H.; Sone, K.; Aoki, S.; Akiko, H.; Kagawa, Y.; Sato, H.; Kunieda, T. Epidermal growth factor receptor-tyrosine kinase inhibitors for non-small-cell lung cancer patients aged 80 years or older: A retrospective analysis. <span class='html-italic'>Mol. Clin. Oncol.</span> <b>2015</b>, <span class='html-italic'>3</span>, 403–407. [<a href="http://scholar.google.com/scholar_lookup?title=Epidermal growth factor receptor-tyrosine kinase inhibitors for non-small-cell lung cancer patients aged 80 years or older: A retrospective analysis&author=Nakao,+M.&author=Muramatsu,+H.&author=Sone,+K.&author=Aoki,+S.&author=Akiko,+H.&author=Kagawa,+Y.&author=Sato,+H.&author=Kunieda,+T.&publication_year=2015&journal=Mol.+Clin.+Oncol.&volume=3&pages=403–407&pmid=25798276" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/25798276" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B22-molecules-21-00189' class='html-xx' data-content='22.'>Koizumi, T.; Sasaki, S.; Sakamoto, A.; Kobayashi, T. Efficacy of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer. <span class='html-italic'>Ann. Palliat. Med.</span> <b>2013</b>, <span class='html-italic'>2</span>, 111–113. [<a href="http://scholar.google.com/scholar_lookup?title=Efficacy of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer&author=Koizumi,+T.&author=Sasaki,+S.&author=Sakamoto,+A.&author=Kobayashi,+T.&publication_year=2013&journal=Ann.+Palliat.+Med.&volume=2&pages=111–113&pmid=25842091" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/25842091" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B23-molecules-21-00189' class='html-xx' data-content='23.'>Nolting, M.; Schneider-Merck, T.; Trepel, M. Lapatinib. <span class='html-italic'>Recent Results Cancer Res.</span> <b>2014</b>, <span class='html-italic'>201</span>, 125–143. [<a href="http://scholar.google.com/scholar_lookup?title=Lapatinib&author=Nolting,+M.&author=Schneider-Merck,+T.&author=Trepel,+M.&publication_year=2014&journal=Recent+Results+Cancer+Res.&volume=201&pages=125–143&pmid=24756789" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/24756789" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B24-molecules-21-00189' class='html-xx' data-content='24.'>Brassard, M.; Rondeau, G. Role of vandetanib in the management of medullary thyroid cancer. <span class='html-italic'>Biologics</span> <b>2012</b>, <span class='html-italic'>6</span>, 59–66. [<a href="http://scholar.google.com/scholar_lookup?title=Role of vandetanib in the management of medullary thyroid cancer&author=Brassard,+M.&author=Rondeau,+G.&publication_year=2012&journal=Biologics&volume=6&pages=59–66&pmid=22500115" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/22500115" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B25-molecules-21-00189' class='html-xx' data-content='25.'>Levitzki, A. Tyrosine kinases as targets for cancer therapy. <span class='html-italic'>Eur. J. Cancer</span> <b>2002</b>, <span class='html-italic'>38</span>, S11–S18. [<a href="http://scholar.google.com/scholar_lookup?title=Tyrosine kinases as targets for cancer therapy&author=Levitzki,+A.&publication_year=2002&journal=Eur.+J.+Cancer&volume=38&pages=S11–S18&pmid=12528768" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/12528768" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B26-molecules-21-00189' class='html-xx' data-content='26.'>Harakeh, S.; Assef, M.D.; El-Sabban, M.; Haddadin, M.; Muhatasib, H.G. Inhibition of proliferation and induction of apoptosis bt 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide in adults T-cell leukemia cells. <span class='html-italic'>Chem. Biol. Interact.</span> <b>2004</b>, <span class='html-italic'>148</span>, 101–113. [<a href="http://scholar.google.com/scholar_lookup?title=Inhibition of proliferation and induction of apoptosis bt 2-benzoyl-3-phenyl-6,7-dichloroquinoxaline 1,4-dioxide in adults T-cell leukemia cells&author=Harakeh,+S.&author=Assef,+M.D.&author=El-Sabban,+M.&author=Haddadin,+M.&author=Muhatasib,+H.G.&publication_year=2004&journal=Chem.+Biol.+Interact.&volume=148&pages=101–113&pmid=15276867" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/15276867" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B27-molecules-21-00189' class='html-xx' data-content='27.'>Levitzki, A. Protein tyrosine kinase inhibitors as noveltherapeutic agents. <span class='html-italic'>Pharmacol. Ther.</span> <b>1999</b>, <span class='html-italic'>82</span>, 231–239. [<a href="http://scholar.google.com/scholar_lookup?title=Protein tyrosine kinase inhibitors as noveltherapeutic agents&author=Levitzki,+A.&publication_year=1999&journal=Pharmacol.+Ther.&volume=82&pages=231–239&pmid=10454200" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/10454200" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B28-molecules-21-00189' class='html-xx' data-content='28.'>Bogoyevitch, M.A.; Fairlie, D.P. A new paradigm for protein kinase inhibition: Blocking phosphorylation without directly targeting ATP binding. <span class='html-italic'>Drug Discov. Today</span> <b>2007</b>, <span class='html-italic'>12</span>, 622–633. [<a href="http://scholar.google.com/scholar_lookup?title=A new paradigm for protein kinase inhibition: Blocking phosphorylation without directly targeting ATP binding&author=Bogoyevitch,+M.A.&author=Fairlie,+D.P.&publication_year=2007&journal=Drug+Discov.+Today&volume=12&pages=622–633&doi=10.1016/j.drudis.2007.06.008&pmid=17706543" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1016/j.drudis.2007.06.008" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/17706543" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B29-molecules-21-00189' class='html-xx' data-content='29.'>Drews, J. Drug discovery: A historical perspective. <span class='html-italic'>Science</span> <b>2000</b>, <span class='html-italic'>287</span>, 1960–1964. [<a href="http://scholar.google.com/scholar_lookup?title=Drug discovery: A historical perspective&author=Drews,+J.&publication_year=2000&journal=Science&volume=287&pages=1960–1964&doi=10.1126/science.287.5460.1960&pmid=10720314" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1126/science.287.5460.1960" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/10720314" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B30-molecules-21-00189' class='html-xx' data-content='30.'>Supuran, C.T.; Casini, A.; Mastrolorenzo, A.; Scozzafava, A. COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. <span class='html-italic'>Mini Rev. Med. Chem.</span> <b>2004</b>, <span class='html-italic'>4</span>, 625–632. [<a href="http://scholar.google.com/scholar_lookup?title=COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents&author=Supuran,+C.T.&author=Casini,+A.&author=Mastrolorenzo,+A.&author=Scozzafava,+A.&publication_year=2004&journal=Mini+Rev.+Med.+Chem.&volume=4&pages=625–632&pmid=15279596" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/15279596" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B31-molecules-21-00189' class='html-xx' data-content='31.'>Abbate, F.; Casini, A.; Owa, T.; Scozzafava, A.; Supuran, C.T. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. <span class='html-italic'>Bioorg. Med. Chem. Lett.</span> <b>2004</b>, <span class='html-italic'>14</span>, 217–223. [<a href="http://scholar.google.com/scholar_lookup?title=Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX&author=Abbate,+F.&author=Casini,+A.&author=Owa,+T.&author=Scozzafava,+A.&author=Supuran,+C.T.&publication_year=2004&journal=Bioorg.+Med.+Chem.+Lett.&volume=14&pages=217–223&pmid=14684331" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/14684331" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B32-molecules-21-00189' class='html-xx' data-content='32.'>Solomon, V.R.; Hu, C.; Lee, H. Hybrid pharmacophore design and synthesis of isatin-benzothiazole analogs for their anti-breast cancer activity. <span class='html-italic'>Bioorg. Med. Chem.</span> <b>2009</b>, <span class='html-italic'>17</span>, 7585–7592. [<a href="http://scholar.google.com/scholar_lookup?title=Hybrid pharmacophore design and synthesis of isatin-benzothiazole analogs for their anti-breast cancer activity&author=Solomon,+V.R.&author=Hu,+C.&author=Lee,+H.&publication_year=2009&journal=Bioorg.+Med.+Chem.&volume=17&pages=7585–7592&doi=10.1016/j.bmc.2009.08.068&pmid=19804979" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1016/j.bmc.2009.08.068" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/19804979" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B33-molecules-21-00189' class='html-xx' data-content='33.'>Ghorab, M.M.; Ragab, F.A.; Heiba, H.I.; El-Gazzar, M.G.; Zahran, S.S. Synthesis, anticancer and radiosensitizing evaluation of some novel sulfonamide derivatives. <span class='html-italic'>Eur. J. Med. Chem.</span> <b>2015</b>, <span class='html-italic'>92</span>, 682–692. [<a href="http://scholar.google.com/scholar_lookup?title=Synthesis, anticancer and radiosensitizing evaluation of some novel sulfonamide derivatives&author=Ghorab,+M.M.&author=Ragab,+F.A.&author=Heiba,+H.I.&author=El-Gazzar,+M.G.&author=Zahran,+S.S.&publication_year=2015&journal=Eur.+J.+Med.+Chem.&volume=92&pages=682–692&doi=10.1016/j.ejmech.2015.01.036&pmid=25618015" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1016/j.ejmech.2015.01.036" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/25618015" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B34-molecules-21-00189' class='html-xx' data-content='34.'>Ghorab, M.M.; Alsaid, M.S.; Ceruso, M.; Nissan, Y.M.; Supuran, C.T. Carbonic anhydrase inhibitors: Synthesis, molecular docking, cytotoxic and inhibition of the human carbonic anhydrase isoforms I, II, IX, XII with novel benzenesulfonamides incorporating pyrrole, pyrrolopyrimidine and fused pyrrolopyrimidine moieties. <span class='html-italic'>Bioorg. Med. Chem.</span> <b>2014</b>, <span class='html-italic'>14</span>, 3684–3695. [<a href="http://scholar.google.com/scholar_lookup?title=Carbonic anhydrase inhibitors: Synthesis, molecular docking, cytotoxic and inhibition of the human carbonic anhydrase isoforms I, II, IX, XII with novel benzenesulfonamides incorporating pyrrole, pyrrolopyrimidine and fused pyrrolopyrimidine moieties&author=Ghorab,+M.M.&author=Alsaid,+M.S.&author=Ceruso,+M.&author=Nissan,+Y.M.&author=Supuran,+C.T.&publication_year=2014&journal=Bioorg.+Med.+Chem.&volume=14&pages=3684–3695" class='google-scholar' target='_blank'>Google Scholar</a>]</li><li id='B35-molecules-21-00189' class='html-xx' data-content='35.'>Ghorab, M.M.; Ceruso, M.; Alsaid, M.S.; Nissan, Y.M.; Arafa, R.K.; Supuran, C.T. Novel sulfonamides bearing pyrrole and pyrrolopyrimidine moieties as carbonic anhydrase inhibitors: Synthesis, cytotoxic activity and molecular modeling. <span class='html-italic'>Eur. J. Med. Chem.</span> <b>2014</b>, <span class='html-italic'>87</span>, 186–196. [<a href="http://scholar.google.com/scholar_lookup?title=Novel sulfonamides bearing pyrrole and pyrrolopyrimidine moieties as carbonic anhydrase inhibitors: Synthesis, cytotoxic activity and molecular modeling&author=Ghorab,+M.M.&author=Ceruso,+M.&author=Alsaid,+M.S.&author=Nissan,+Y.M.&author=Arafa,+R.K.&author=Supuran,+C.T.&publication_year=2014&journal=Eur.+J.+Med.+Chem.&volume=87&pages=186–196&pmid=25255434" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/25255434" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B36-molecules-21-00189' class='html-xx' data-content='36.'>Ghorab, M.M.; El-Gazzar, M.G.; Alsaid, M.S. Synthesis and Anti-Breast Cancer Evaluation of Novel <span class='html-italic'>N</span>-(Guanidinyl)-benzenesulfonamides. <span class='html-italic'>Int. J. Mol. Sci.</span> <b>2014</b>, <span class='html-italic'>15</span>, 5582–5595. [<a href="http://scholar.google.com/scholar_lookup?title=Synthesis and Anti-Breast Cancer Evaluation of Novel N-(Guanidinyl)-benzenesulfonamides&author=Ghorab,+M.M.&author=El-Gazzar,+M.G.&author=Alsaid,+M.S.&publication_year=2014&journal=Int.+J.+Mol.+Sci.&volume=15&pages=5582–5595&doi=10.3390/ijms15045582&pmid=24694543" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.3390/ijms15045582" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/24694543" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B37-molecules-21-00189' class='html-xx' data-content='37.'>Ghorab, M.M.; El-Gazzar, M.G.; Alsaid, M.S. Synthesis, Characterization and Anti-Breast Cancer Activity of New 4-Aminoantipyrine-Based Heterocycles. <span class='html-italic'>Int. J. Mol. Sci.</span> <b>2014</b>, <span class='html-italic'>15</span>, 7539–7553. [<a href="http://scholar.google.com/scholar_lookup?title=Synthesis, Characterization and Anti-Breast Cancer Activity of New 4-Aminoantipyrine-Based Heterocycles&author=Ghorab,+M.M.&author=El-Gazzar,+M.G.&author=Alsaid,+M.S.&publication_year=2014&journal=Int.+J.+Mol.+Sci.&volume=15&pages=7539–7553&pmid=24798749" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/24798749" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B38-molecules-21-00189' class='html-xx' data-content='38.'>Al-Dosari, M.S.; Ghorab, M.M.; Alsaid, M.S.; Nissan, Y.M.; Ahmed, A.B. Synthesis and anticancer activity of some novel trifluoromethylquinolines carrying a biologically active benzenesulfonamide moiety. <span class='html-italic'>Eur. J. Med. Chem.</span> <b>2013</b>, <span class='html-italic'>69</span>, 373–383. [<a href="http://scholar.google.com/scholar_lookup?title=Synthesis and anticancer activity of some novel trifluoromethylquinolines carrying a biologically active benzenesulfonamide moiety&author=Al-Dosari,+M.S.&author=Ghorab,+M.M.&author=Alsaid,+M.S.&author=Nissan,+Y.M.&author=Ahmed,+A.B.&publication_year=2013&journal=Eur.+J.+Med.+Chem.&volume=69&pages=373–383&doi=10.1016/j.ejmech.2013.08.048&pmid=24077528" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1016/j.ejmech.2013.08.048" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/24077528" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B39-molecules-21-00189' class='html-xx' data-content='39.'>Ghorab, M.M.; Ragab, F.A.; Heiba, H.I.; El-Hazek, R.M. Anticancer and radio-sensitizing evaluation of some new thiazolopyrane and thiazolopyranopyrimidine derivatives bearing a sulfonamide moiety. <span class='html-italic'>Eur. J. Med. Chem.</span> <b>2011</b>, <span class='html-italic'>46</span>, 5120–5126. [<a href="http://scholar.google.com/scholar_lookup?title=Anticancer and radio-sensitizing evaluation of some new thiazolopyrane and thiazolopyranopyrimidine derivatives bearing a sulfonamide moiety&author=Ghorab,+M.M.&author=Ragab,+F.A.&author=Heiba,+H.I.&author=El-Hazek,+R.M.&publication_year=2011&journal=Eur.+J.+Med.+Chem.&volume=46&pages=5120–5126&doi=10.1016/j.ejmech.2011.08.026&pmid=21890248" class='google-scholar' target='_blank'>Google Scholar</a>] [<a href="http://dx.doi.org/10.1016/j.ejmech.2011.08.026" class='cross-ref' target='_blank'>CrossRef</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/21890248" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B40-molecules-21-00189' class='html-xx' data-content='40.'>Al-Said, M.S.; Ghorab, M.M.; Al-Dosari, M.S.; Hamed, M.M. Synthesis and <span class='html-italic'>in vitro</span> anticancer evaluation of some novel hexahydroquinoline derivatives having a benzenesulfonamide moiety. <span class='html-italic'>Eur. J. Med. Chem.</span> <b>2011</b>, <span class='html-italic'>46</span>, 201–207. [<a href="http://scholar.google.com/scholar_lookup?title=Synthesis and in vitro anticancer evaluation of some novel hexahydroquinoline derivatives having a benzenesulfonamide moiety&author=Al-Said,+M.S.&author=Ghorab,+M.M.&author=Al-Dosari,+M.S.&author=Hamed,+M.M.&publication_year=2011&journal=Eur.+J.+Med.+Chem.&volume=46&pages=201–207&pmid=21112675" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/21112675" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B41-molecules-21-00189' class='html-xx' data-content='41.'>Ghorab, M.M.; Ragab, F.A.; Heiba, H.I.; Youssef, H.A.; El-Gazzar, M.G. Synthesis of novel pyrrole and pyrrolo [2,3-d] pyrimidine derivatives bearing sulfonamide moiety for evaluation as anticancer and radiosensitizing agents. <span class='html-italic'>Bioorg. Med. Chem. Lett.</span> <b>2010</b>, <span class='html-italic'>20</span>, 6316–6320. [<a href="http://scholar.google.com/scholar_lookup?title=Synthesis of novel pyrrole and pyrrolo [2,3-d] pyrimidine derivatives bearing sulfonamide moiety for evaluation as anticancer and radiosensitizing agents&author=Ghorab,+M.M.&author=Ragab,+F.A.&author=Heiba,+H.I.&author=Youssef,+H.A.&author=El-Gazzar,+M.G.&publication_year=2010&journal=Bioorg.+Med.+Chem.+Lett.&volume=20&pages=6316–6320&pmid=20850308" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/20850308" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B42-molecules-21-00189' class='html-xx' data-content='42.'>Al-Said, M.S.; Ghorab, M.M.; Al-Qasoumi, S.I.; El-Hossary, E.M.; Noaman, E. Synthesis and <span class='html-italic'>in vitro</span> anticancer screening of some novel 4-[2-amino-3-cyano-4-substituted-5,6,7,8-tetrahydroquinolin-1-(4<span class='html-italic'>H</span>)-yl]benzenesulfonamides. <span class='html-italic'>Eur. J. Med. Chem.</span> <b>2011</b>, <span class='html-italic'>45</span>, 3011–3018. [<a href="http://scholar.google.com/scholar_lookup?title=Synthesis and in vitro anticancer screening of some novel 4-[2-amino-3-cyano-4-substituted-5,6,7,8-tetrahydroquinolin-1-(4H)-yl]benzenesulfonamides&author=Al-Said,+M.S.&author=Ghorab,+M.M.&author=Al-Qasoumi,+S.I.&author=El-Hossary,+E.M.&author=Noaman,+E.&publication_year=2011&journal=Eur.+J.+Med.+Chem.&volume=45&pages=3011–3018" class='google-scholar' target='_blank'>Google Scholar</a>]</li><li id='B43-molecules-21-00189' class='html-xx' data-content='43.'>Alqasoumi, S.I.; Al-Taweel, A.M.; Alafeefy, A.M.; Ghorab, M.M.; Noaman, E. Discovering some novel tetrahydroquinoline derivatives bearing the biologically active sulfonamide moiety as a new class of antitumor agents. <span class='html-italic'>Eur. J. Med. Chem.</span> <b>2010</b>, <span class='html-italic'>45</span>, 1849–1853. [<a href="http://scholar.google.com/scholar_lookup?title=Discovering some novel tetrahydroquinoline derivatives bearing the biologically active sulfonamide moiety as a new class of antitumor agents&author=Alqasoumi,+S.I.&author=Al-Taweel,+A.M.&author=Alafeefy,+A.M.&author=Ghorab,+M.M.&author=Noaman,+E.&publication_year=2010&journal=Eur.+J.+Med.+Chem.&volume=45&pages=1849–1853&pmid=20149941" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/20149941" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B44-molecules-21-00189' class='html-xx' data-content='44.'>Alqasoumi, S.I.; Al-Taweel, A.M.; Alafeefy, A.M.; Noaman, E.; Ghorab, M.M. Novel quinolines and pyrimido[4,5-b]quinolines bearing biologically active sulfonamide moiety as a new class of antitumor agents. <span class='html-italic'>Eur. J. Med. Chem.</span> <b>2010</b>, <span class='html-italic'>45</span>, 738–744. [<a href="http://scholar.google.com/scholar_lookup?title=Novel quinolines and pyrimido[4,5-b]quinolines bearing biologically active sulfonamide moiety as a new class of antitumor agents&author=Alqasoumi,+S.I.&author=Al-Taweel,+A.M.&author=Alafeefy,+A.M.&author=Noaman,+E.&author=Ghorab,+M.M.&publication_year=2010&journal=Eur.+J.+Med.+Chem.&volume=45&pages=738–744&pmid=19944497" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/19944497" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B45-molecules-21-00189' class='html-xx' data-content='45.'>Ghorab, M.M.; Ragab, F.A.; Hamed, M.M. Design, synthesis and anticancer evaluation of novel tetrahydroquinoline derivatives containing sulfonamide moiety. <span class='html-italic'>Eur. J. Med. Chem.</span> <b>2009</b>, <span class='html-italic'>44</span>, 4211–4217. [<a href="http://scholar.google.com/scholar_lookup?title=Design, synthesis and anticancer evaluation of novel tetrahydroquinoline derivatives containing sulfonamide moiety&author=Ghorab,+M.M.&author=Ragab,+F.A.&author=Hamed,+M.M.&publication_year=2009&journal=Eur.+J.+Med.+Chem.&volume=44&pages=4211–4217&pmid=19540022" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/19540022" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li><li id='B46-molecules-21-00189' class='html-xx' data-content='46.'>Paul, K.; Sharma, A.; Luxami, V. Synthesis and <span class='html-italic'>in vitro</span> antitumor evaluation of primary amine substituted quinazoline linked benzimidazole. <span class='html-italic'>Bioorg. Med. Chem. Lett.</span> <b>2014</b>, <span class='html-italic'>24</span>, 624–629. [<a href="http://scholar.google.com/scholar_lookup?title=Synthesis and in vitro antitumor evaluation of primary amine substituted quinazoline linked benzimidazole&author=Paul,+K.&author=Sharma,+A.&author=Luxami,+V.&publication_year=2014&journal=Bioorg.+Med.+Chem.+Lett.&volume=24&pages=624–629&pmid=24360999" class='google-scholar' target='_blank'>Google Scholar</a>]  [<a href="http://www.ncbi.nlm.nih.gov/pubmed/24360999" class='cross-ref' data-typ='pmid' target='_blank'>PubMed</a>]</li></ol></section><section class='html-fn_group'><ul><li><div class='html-p' style='text-indent:0em;'><span class='html-fn-content'><b>Sample Availability:</b> Not available.</span></div></li></ul></section>
    <section><p id="html-copyright">© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).</p></section>
  </div>
</article>
<style type="text/css">
  body{
    font-size: 11pt;
  }
</style>

</div>
<div class="clear"></div>
<div class="journal-info">
   <em><a href="/journal/molecules">Molecules</a></em>
   <span>EISSN 1420-3049</span>
   <span>Published by MDPI AG, Basel, Switzerland</span>
   <span><a href="/rss/journal/molecules">RSS</a></span>
   <span><a href="/journal/molecules/toc-alert">E-Mail Table of Contents Alert</a></span>
   </div>
                    </div>
                                        <div id="footer">
                        <ul>
                            <li><a href="/about/termsofuse">Terms &amp; Conditions</a></li>
                            <li><a href="/about/privacy">Privacy Policy</a></li>
                            <li><a href="/about/contact">Contact MDPI</a></li>
                            <li><a href="/about/jobs">Jobs at MDPI</a>
                        </ul>
                        <div id="copyright">&copy; 1996-2016 MDPI AG (Basel, Switzerland) unless otherwise stated</div>
                    </div>
                </div>
            </div>
        </div>
        
        <script src="http://img.mdpi.org/assets/js/first.js?06682939da1c3ece"></script>
        <script type="text/javascript">mdpiConfig('static_base_url', 'http://img.mdpi.org')</script>
        <script src="http://img.mdpi.org/assets/js/lib.js?e3cdff0ca6024bde"></script>
        <script src="http://img.mdpi.org/assets/js/main.js?a6d059ade3334abe"></script>
        <script>var banners_url = 'http://serve.mdpi.com';</script>
		<script type='text/javascript' src='http://img.mdpi.org/assets/js/serve-banner.js?2b7a1a93e8eb776c'></script>		
          <script src="http://img.mdpi.org/assets/js/article-html.js?951760f20a41de5e"></script>
  <script type="text/javascript">
    $('document').ready(function(){
      if(1 == 0){
        var doi = $('.html-art-header').find('a');
        var text = doi.text();
        doi.remove();
        $('.html-art-header p').append(text);
      }
      $('#maincol').css('position','static')
    });
  </script>


                  <script type="text/javascript">_uacct = "UA-5824718-2"; urchinTracker();</script>
            </body>
</html>
